

Commission Directive 2009/2/EC of 15 January 2009 amending, for the purpose of its adaptation to technical progress, for the 31st time, Council Directive 67/548/EEC on the approximation of the laws, regulations and administrative provisions relating to the classification, packaging and labelling of dangerous substances (Text with EEA relevance)

COMMISSION DIRECTIVE 2009/2/EC

of 15 January 2009

amending, for the purpose of its adaptation to technical progress, for the 31st time, Council Directive 67/548/EEC on the approximation of the laws, regulations and administrative provisions relating to the classification, packaging and labelling of dangerous substances

(Text with EEA relevance)

THE COMMISSION OF THE EUROPEAN COMMUNITIES,

Having regard to the Treaty establishing the European Community,

Having regard to Council Directive 67/548/EEC of 27 June 1967 on the approximation of the laws, regulations and administrative provisions relating to the classification, packaging and labelling of dangerous substances<sup>(1)</sup>, and in particular Article 28 thereof,

Whereas:

- (1) Article 4(3) of Directive 67/548/EEC sets out the criteria and the procedure to be followed to harmonise the classification and labelling of substances. Paragraphs 4.1.3, 4.1.4 and 4.1.5 of Annex VI to Directive 67/548/EEC oblige industry to provide information to Member States and Member States to make proposals for harmonised classification and labelling as a matter of urgency, when information becomes available justifying that a substance fulfils the criteria as a mutagenic, carcinogenic or reproductive toxic chemical.
- (2) Annex I to Directive 67/548/EEC contains a list of dangerous substances, together with particulars of the classification and labelling of each substance. That list needs to be updated to include further notified new substances and further existing substances, as well as to adapt certain entries to technical progress. In addition, it is necessary, in that Annex, to delete entries for certain substances.
- (3) Annex I to Directive 67/548/EEC already contains numerous group entries in particular for metal compounds evaluated using a grouping and read across approach based on analogy between substances.
- (4) Annex I to Directive 67/548/EEC also contains certain groups where members of the group are identified and where the classification was derived by applying grouping and read across approaches, notably the petroleum streams and gasses.

---

*Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.*

---

- (5) Annex VI to Directive 67/548/EEC states that the data required for classification and labelling may be obtained from a number of different sources, including the results of validated structure-activity relationships and expert judgement.
- (6) The classifications of the nickel compounds listed in this Directive are based on the effects originating from the Ni(2+) ion and on the available data for nickel compounds. The classifications were derived by grouping nickel compounds into categories on the basis of water solubility (e.g. groups insoluble, slightly soluble and soluble nickel compounds respectively). Water solubility was used as an initial criterion to define these categories, based on the argument that nickel substances having similar water solubility will indicate similar bioavailability of the Ni(2+) ion and similar systemic toxicity. This justifies a read across within groups from the substances for which the available adequate test data demonstrate a specific systemic effect to those lacking such test data. For some effects, read across between groups is justified, as similar effects have been observed across the range of water solubility. For example, epidemiological studies show that both soluble and insoluble nickel compounds (at opposite ends of the range of solubility) have local carcinogenic effects in the respiratory tract. There is, therefore, good reason to conclude that slightly soluble compounds (at the middle of this range) have similar carcinogenic properties.
- (7) As part of an evaluation of all the available information for the nickel compounds, water solubility can be used as an approximation of systemic bioavailability of the Ni(2+) ion for many effects and substances.
- (8) The classification and labelling of the substances listed in this Directive should be reviewed if new scientific knowledge becomes available. In this context, noting in particular that the nickel industry has recently submitted preliminary, partial and not peer-reviewed information, special attention should be paid to the outcome of future discussions within the World Health Organisation's International Agency for Research on Cancer on the carcinogenicity of nickel substances, or to any relevant new scientific findings or interpretations of the data used to establish the classifications for the nickel compounds included in this Directive.
- (9) The measures provided for in this Directive are in accordance with the opinion of the Committee on the Adaptation to Technical Progress of the Directives for the Elimination of Technical Barriers to Trade with Dangerous Substances and Preparations,

HAS ADOPTED THIS DIRECTIVE:

*Article 1*

Directive 67/548/EEC is amended as follows. Annex I is amended as follows:

- (a) the entries corresponding to the entries set out in Annex 1A to this Directive are replaced by the entries set out in that Annex;
- (b) the entries set out in Annex 1B to this Directive are inserted in accordance with the order of the entries set out in Annex I to Directive 67/548/EEC;
- (c) the entries set out in Annex 1C to this Directive are deleted.

---

*Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.*

---

#### *Article 2*

Member States shall bring into force the laws, regulations and administrative provisions necessary to comply with this Directive by 1 June 2009 at the latest. They shall forthwith communicate to the Commission the text of those provisions and a correlation table between those provisions and this Directive.

When Member States adopt those provisions, they shall contain a reference to this Directive or be accompanied by such a reference on the occasion of their official publication. Member States shall determine how such reference is to be made.

Member States shall communicate to the Commission the text of the main provisions of national law which they adopt in the field covered by this Directive.

#### *Article 3*

This Directive shall enter into force on the twentieth day following that of its publication in the *Official Journal of the European Union*.

#### *Article 4*

This Directive is addressed to the Member States.

Done at Brussels, 15 January 2009.

*For the Commission*

Stavros DIMAS

*Member of the Commission*

*Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.*

## ANNEX 1A

Index No	Chemical name	Notes related to substances	EC No	CAS No	Classification	Labelling	Concentration Limits	Notes related to preparations
001-002-001	Aluminium lithium hydride		240-877-9	16853-85	F; R15 C; R35	F; C R: 15-35 S: (1/2-)7/8-26-36/37/39-43-45		
005-006-001	n-Butyltin hydrogen borate	E	401-040-5	575113-37	Muta. Cat. 3; R68 Repr. Cat. 2; R60-61 T; R48/25 Xn; R21/22 Xi; R41 R43 N; R50-53	T; N R: 60-61-21/22-41-43-48/25-68-50/53 S: 53-45-60-61		
006-007-001	Salts of hydrogen cyanide with the exception of complex cyanides such as ferrocyanides, ferricyanides and mercuric oxycyanide and those specified elsewhere in this Annex	A	—	—	T+; R26/27/28 R32 N; R50-53	T+; N R: 26/27/28-32-50/53 S: (1/2-)7-28-29-45-60-61		
006-015-001	Iron (ISO); 3-(3,4-dichlorophenyl)-1,1-dimethylurea		206-354-4	330-54-1	Carc. Cat. 3; R40 Xn; R22-48/22 N; R50-53	Xn; N R: 22-40-48/22-50/53 S: (2-)13-36/37-46-60-61	C ≥ 25 %: 22-40-48/22-50/53 R22-40-48/22-50/53 10-46-60-61 ≤ C < 25 %:	

*Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.*

							Xn, N; R40-48/22-50/53 2,5 % ≤ C < 10 %: Xn, N; R40-50/53 1 % ≤ C < 2,5 %: Xn, N; R40-51/53 0,25 % ≤ C < 1 %: N; R51/53 0,025 % ≤ C < 0,25 %: R52/53
006-076-001	mancozeb (ISO); manganese ethylenebis(dithiocarbamate) (polymeric) complex with zinc salt	—	8018-01-7	Repr. Cat. 3; R63 R43 N; R50	Xn; N R: 43-63-50 S: (2-)36/37-46/50	C ≥ 5 %: Xn, N; R43-63-50 2,5 ≤ C ≤ C < 1 %: Xi, N; R43-50 1 % ≤ C < 2,5 %: Xi; R43	
006-077-001	mancozeb (ISO); manganese ethylenebis(dithiocarbamate) (polymeric)	235-654-8	12427-38	Repr. Cat. 3; R63 Xn; R20 Xi; R36 R43 N; R50-53	Xn; N R: 20-36-43-63-50/53 S: (2-)36/37-46/61	C ≥ 25 %: Xn, N; R20-36-43-63-50/53 20-36-43-63-50/53 ≤ C < 25 %: Xn, N; R36-43-63-50/53 5 % ≤ C < 20 %: Xn, N; R43-63-50/53 2,5 % ≤ C < 5 %: Xi, N; R43-50/53 1 % ≤ C < 2,5 %: Xi, N; R43-51/53 0,25 % ≤ C <	

*Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.*

							1 %: N; R51/53 0,025 % ≤ C < 0,25 %: R52/53	
006-084-005	fenobosulfan (ISO); 2,3- dihydro-2,2- dimethyl-7- benzofuryl [(dibutylamino)thio]methylcarbamate	259-565-9	55285-14	8+; R26 T; R25 R43 N; R50-53	T+; N R: 25-26-43-50/53 S: (1/2-)28-36/37-38-45-63-60-61			
006-088-007	fenfuracarb (ISO); ethyl N-[2,3- dihydro-2,2- dimethylbenzofuran-7- yloxycarbonyl(methyl)aminothio]-N- isopropyl- β- alaninate	—	82560-54	Repr. Cat. 3; R62 T; R23 Xn; R22 N; R50-53	T; N R: 22-23-62-50/53 S: (1/2-)36/37-45-60-61			
007-002-001	nitrogen dioxide; [1] dinitrogen tetraoxide [2]	233-272-6 234-126-4	10102-44 10344-72	O; R8 C; R26 C; R34	O; T+ R: 8-26-34 S: (1/2-)9-26-28-36/37/39-45	C ≥ 10 %: T+; R26-34 ≤ C < 10 %: T; R23-34 1 % ≤ C < 5 %: T; R23-36/37/38 0,5 % ≤ C < 1 %: Xn; R20-36/37/38 0,1 % ≤ C < 0,5 %: Xn; R20	5	
015-041-001 X	malathion (ISO); 1,2- bis(ethoxycarbonyl)ethyl O,O- dimethyl phosphorodithioate;	204-497-7	121-75-5	Xn; R22 R43 N; R50-53	Xn; N R: 22-43-50/53 S: (2-)24-37-40-60-61	C ≥ 25 %: Xn, N; R22-43-50/53 < 25 %: Xi, N; R43-50/53		

**Status:** EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

	[containing ≤ 0,03 % isomalathion]						0,025 % ≤ C < 1 %: N; R50/53 0,0025 % ≤ C < 0,025 %: N; R51/53 0,00025 % ≤ C < 0,0025 %: R52/53
015-100-00 X	Phoxim (ISO); α- (diethoxyphosphinothioylimino) phenylacetonitrile		238-887-3 14816-18	Repr. Cat. 3; R62 Xn; R22 R43 N; R50-53	Xn; N R: 22-43-62-50/53 S: (2-)36/37-40/60-61		C ≥ 25 %: 50/53; R22-43-62-50/53 40/60-61 < 25 %: Xn, N; R43-62-50/53 1 % ≤ C < 5 %: Xi, N; R43-50/53 0,025 % ≤ C < 1 %: N; R50/53 0,0025 % ≤ C < 0,025 %: N; R51/53 0,00025 % ≤ C < 0,0025 %: R52/53
015-102-00 E	(2-chloroethyl)phosphate	E	204-118-5 115-96-8	Carc. Cat. 3; R40 Repr. Cat. 2; R60 Xn; R22 N; R51-53	T; N R: 60-22-40-51/53 S: 53-45-61		
015-155-00 X	Glyfosinat ammonium (ISO); ammonium 2-	E	278-636-5 77182-82	Repr. Cat. 2; R60	T R: 60-20/21/22-48/20/22-63 S: 53-45		

*Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.*

	amino-4-(hydroxymethylphosphinyl)butyrate				Repr. Cat. 3; R63 Xn; R20/21/22-48/20/22			
016-009-0018	Sodium sulfide; sodium sulfide		215-211-5	1313-82-2	T; R24 Xn; R22 C; R34 R31 N; R50	T; C; N R: 22-24-31-34-50 S: (1/2-)26-36/37/39-45-61		
017-009-0010	Ammonium perchlorate; [containing ≥ 80 % of 0-30 µm particles]		232-235-1	7790-98-9	E; R3 O; R9	E R: 3-9 S: (2-)14-16-36/37		
024-004-0067	Mercuric dichromate	E	234-190-3	10588-01-0	O; R8 Carc. Cat. 2; R45 Muta. Cat. 2; R46 Repr. Cat. 2; R60-61 T+; R26 T; R25-48/23 Xn; R21 C; R34 R42/43 N; R50-53	O; T+; N R: 45-46-60-61-48-26-36-34-23-25-48-23-30-53 S: 53-45-60-61 C < 25 %: T+, N; R45-46-60-61-22-26-34-42/43-48/23-51 7 % ≤ C < 10 %: T+, N; R45-46-60-61-22-26-36/37/38-42/43-48 5 % ≤ C < 7 %: T, N; R45-46-60-61-22-23-36/37/38-42/43-48 3 % ≤ C < 5 %: T, N; R45-46-60-61-22-23-42/43-48/20-51/53 2,5 % ≤ C < 3 %: T, N; R45-46-60-61-23-42/43-48/20-51/53 1 % ≤ C < 2,5 %: T; R45-46-60-61-23-42/43-48/20-52/53 0,5 % ≤ C < 1 %: T; R45-46-60-61-20-42/43-52/53	C ≥ 25 %: T+, N; 10 % ≤ C < 25 %: T+, N; R45-46-60-61-22-26-34-42/43-48/23-51 7 % ≤ C < 10 %: T+, N; R45-46-60-61-22-26-36/37/38-42/43-48 5 % ≤ C < 7 %: T, N; R45-46-60-61-22-23-36/37/38-42/43-48 3 % ≤ C < 5 %: T, N; R45-46-60-61-22-23-42/43-48/20-51/53 2,5 % ≤ C < 3 %: T, N; R45-46-60-61-23-42/43-48/20-51/53 1 % ≤ C < 2,5 %: T; R45-46-60-61-23-42/43-48/20-52/53 0,5 % ≤ C < 1 %: T; R45-46-60-61-20-42/43-52/53	3



*Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.*

						0,25 % ≤ C < 0,5 %: T; R45-46-20-42/43-52/53 0,2 % ≤ C < 0,25 %: T; R45-46-20-42/43 0,1 % ≤ C < 0,2 %: T; R45-46-20	
027-002-004	cobalt oxide	215-154-6	1307-96-6	Xn; R22 R43 N; R50-53	Xn; N R: 22-43-50/53 S: (2-)24-37-05-06	C ≥ 25 %: Xn, N; R22-43-50/53 0,5 % ≤ C < 25 %: Xi, N; R43-50/53 1 % ≤ C < 2,5 %: Xi, N; R43-51/53 0,25 % ≤ C < 1 %: N; R51/53 0,025 % ≤ C < 0,25 %: R52/53	
027-003-004 X	cobalt sulfide	215-273-3	1317-42-6	R43 N; R50-53	Xi; N R: 43-50/53 S: (2-)24-37-05-06	C ≥ 2,5 %: Xi, N; R43-50/53 1 % ≤ C < 2,5 %: Xi, N; R43-51/53 0,25 % ≤ C < 1 %: N; R51/53 0,025 % ≤ C <	

*Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.*

							0,25 %: R52/53	
028-003-0012	nickel monoxide; [1] nickel oxide; [2] bunsenite [3]	E	215-215-7 [3] 234-323-5 [2] - [3]	13-99-1 [1] 099-02-8 [2] 34492-97-2 [3]	Carc. Cat. 1; R49 T; R48/23 R43 R53	T R: 49-43-48/23-53 S: 53-45-61		
028-004-0018	nickel dioxide	E	234-823-3	12035-36	Carc. Cat. 1; R49 T; R48/23 R43 R53	T R: 49-43-48/23-53 S: 53-45-61		
028-005-0013	nickel trioxide	E	215-217-8	1314-06-3	Carc. Cat. 1; R49 T; R48/23 R43 R53	T R: 49-43-48/23-53 S: 53-45-61		
028-006-0010	nickel (II) sulfide; [1] nickel sulfide; [2] millerite [3]	E	240-841-2 [6] 234-349-7 [2] - [3]	12-54-0 [1] 13-75-0 [2] 1314-04-1	Carc. Cat. 1; R49 Muta. Cat. 3; R68 T; R48/23 R43 N; R50-53	T; N R: 49-43-48/23-68-50/53 S: 53-45-60-61		
028-007-0014	nickel disulfide; nickel subsulfide; [1] heazlewoodite [2]	E	234-829-6 [2] - [2]	12035-72-1 [1] 12035-71-9 [2]	Carc. Cat. 1; R49 Muta. Cat. 3; R68 T; R48/23 R43 N; R50-53	T; N R: 49-43-48/23-68-50/53 S: 53-45-60-61		
028-008-001X	nickel dihydroxide; [1] nickel hydroxide [2]	E	235-008-5 [2] 234-348-1 [2]	12054-48-9 [1] 13-74-9 [2]	Carc. Cat. 1; R49 Repr. Cat. 2; R61 Muta. Cat. 3; R68 T; R48/23	T; N R: 49-61-20/22-38-42/43-48/23-68-50/53 S: 53-45-60-61		

*Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.*

					Xn; R20/22 Xi; R38 R42/43 N; R50-53			
029-013-00 X	001 Sodium (2-( $\alpha$ -(3-(4- chloro-6- (2-(2- (vinylsulfonyl)ethoxy)ethylamino)-1,3,5- triazin-2- ylamino)-2- oxido-5- sulfonatophenylazo)benzylidenehydrazino)-4- sulfonatobenzoato)copper(II)	AE	407-580-8	130201-5	Xn; R41	Xi R: 41 S: (2-)26-39		
033-005-00	001 Arsenic acid and its salts with the exception of those specified elsewhere in this Annex	AE	—	—	Carc. Cat. 1; R45 T; R23/25 N; R50-53	T; N R: 45-23/25-50/53 S: 53-45-60-61		
034-002-00	001 Selenium compounds with the exception of cadmium sulphoselenide and those specified elsewhere in this Annex	A	—	—	T; R23/25 R33 N; R50-53	T; N R: 23/25-33-50/53 S: (1/2-)20/21-28-45-60-61		
047-001-00	001 Mer nitrate		231-853-9	7761-88-8	O; R8 C; R34 N; R50-53	O; C; N R: 8-34-50/53 S: (1/2-)26-36/37/39-45-60-61		
050-002-00	001 Hexatin (ISO); hydroxytricyclohexylstannane; tri(cyclohexyl)tin hydroxide		236-049-1	13121-70-	Xn; R20/21/22 N; R50-53	Xn; N R: 20/21/22-50/53 S: (2-)13-60-61	C $\geq$ 25 %: Xn; N; R20/21/22-50/53 0,025 % $\leq$ C <	

*Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.*

						25 %: N; R50/53 0,0025 % ≤ C < 0,025 %: N; R51/53 0,00025 % ≤ C < 0,0025 %: R52/53
050-003-006	Centin acetate (ISO); triphenyltin acetate	212-984-0900-95-8	Carc. Cat. 3; R40 Repr. Cat. 3; R63 T+; R26 T; R24/25-48/23 Xi; R37/38-41 N; R50-53	T+; N R: 24/25-26-37/38-40-41-48/23-63-50/53 S: (1/2-)26-28/37/39-45-60-61	C ≥ 25 %: R: 24/25-26-37/38-40-41-48/23-63-50/53 S: (1/2-)26-28/37/39-45-60-61 ≤ C < 25 %: T+, N; R21/22-26-37/38-40-41-48/23-63-50/53 10 % ≤ C < 20 %: T+, N; R21/22-26-40-41-48/23-63-50/53 7 % ≤ C < 10 %: T+, N; R21/22-26-36-40-48/20-63-50/53 5 % ≤ C < 7 %: T, N; R21/22-23-36-40-48/20-63-50/53 3 % ≤ C < 5 %: T, N; R21/22-23-40-48/20-50/53 2,5 % ≤ C < 3 %: T, N; R23-40-48/20-50/53 1 % ≤ C < 2,5 %: T, N; R23-40-48/20-51/53 0,25 % ≤ C < 1 %: Xn, N; R20-51/53	

**Status:** EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

						0,1 % ≤ C < 0,25 %: Xn; R20-52/53
						0,025 % ≤ C < 0,1 %: R52/53
050-004-00	Cent hydroxide (ISO); triphenyltin hydroxide		200-990-676-87-9	Carc. Cat. 3; R40 Repr. Cat. 3; R63 T+; R26 T; R24/25-48/23 Xi; R37/38-41 N; R50-53	T+; N R: 24/25-26-37/38-40-41-48/23-63-50/53 S: (1/2-)26-28/37/39-45-60-61	C ≥ 25 %: R24/25-26-37/38-40-41-48/23-63-50/53 R21/22-26-37/38-40-41-48/23-63-50/53 ≤ C < 25 %: T+, N; R21/22-26-37/38-40-41-48/23-63-50/53 10 % ≤ C < 20 %: T+, N; R21/22-26-40-41-48/23-63-50/53 7 % ≤ C < 10 %: T+, N; R21/22-26-36-40-48/20-63-50/53 5 % ≤ C < 7 %: T, N; R21/22-23-36-40-48/20-63-50/53 3 % ≤ C < 5 %: T, N; R21/22-23-40-48/20-50/53 2,5 % ≤ C < 3 %: T, N; R23-40-48/20-50/53 1 % ≤ C < 2,5 %: T, N; R23-40-48/20-51/53 0,25 % ≤ C < 1 %: Xn, N; R20-51/53 0,1 % ≤ C < 0,25 %:

*Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.*

							Xn; R20-52/53 0,025 % ≤ C < 0,1 %: R52/53	
050-008-001	Di-n-butyltin A compounds, with the exception of those specified elsewhere in this Annex		—	—	T; R25-48/23 Xn; R21 Xi; R36/38 N; R50-53	T; N R25 21-25-36/38-48/23/25-50/53 S: (1/2-)36/37/39-45-60-61	C ≥ 2,5 %: R21-25-36/38-48/23/25-50/53 < 2,5 %: T, N; R21-25-36/38-48/23/25-51/53 0,25 % ≤ C < 1 %: Xn, N; R22-48/20/22-51/53 0,025 % C < 0,25 %: R52/53	1
050-011-001 X	Diphenyltin A compounds, with the exception of those specified elsewhere in this Annex		—	—	T; R23/24/25 N; R50-53	T; N R: 23/24/25-50-53/24/25-50/53 S: (1/2-)26-27-28-45-60-61	C ≥ 1 %: T, N; R23/24/25-50-53/24/25-50/53 0,25 % 1 %: Xn, N; R20/21/22-50/53 0,025 % ≤ C < 0,25 %: N; R51/53 0,0025 % ≤ C < 0,025 %: R52/53	1
050-018-001	(II) methanesulphonate	401-640-753	408-94-0	0	C; R34 Xn; R22 R43 N; R51-53	C; N R: 22-34-43-51/53 S: (1/2-)22-26-36/37/39-45-61		
053-003-001	4-iodoxybenzene	—	696-33-3		E; R2	E R: 2 S: (2-)35		
053-004-001 X	calcium C iodoxybenzoate	—	—		E; R2	E R: 2		

*Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.*

					S: (2-)	35	
080-001-00	Mercury	E	231-106-77439-97-6	Repr. Cat. 2; R61 T+; R26 T; R48/23 N; R50-53	T+; N R: 61-26-48/23-50/53 S: 53-45-60-61		
080-010-00 X	Mercury dichloride; mercuric chloride		231-299-87487-94-7	Muta. Cat. 3; R68 Repr. Cat. 3; R62 T+; R28 T; R48/24/25 C; R34 N; R50-53	T+; N R: 28-34-48/24/25-62-68-50/53 S: (1/2-)26-36/37/39-45-60-61		
092-002-00	Uranium compounds with the exception of those specified elsewhere in this Annex	A	—	—	T+; R26/28 R33 N; R51-53	T+; N R: 26/28-33-51/53 S: (1/2-)20/21-45-61	
601-065-00	3 mixture of: (1'α,3'α,6(α)-2,2,3',7',7'- pentamethylspiro(1,3- dioxane-5,2'- norcarane); (1'α,3'β,6(α)-2,2,3',7',7'- pentamethylspiro(1,3- dioxane-5,2'- norcarane)		416-930-9	—	Xi; R38 N; R51-53	Xi; N R: 38-51/53 S: (2-)36/37-61	
602-007-00 X	Bromoform; tribromomethane		200-854-675-25-2	T; R23 Xn; R22 Xi; R36/38 N; R51-53	T; N R: 22-23-36/38-51/53 S: (1/2-)28-45-63-61		
602-030-00	3- dichloropropene; [1]	C D	208-826-544-75-6 233-195-81061-01	[R]10 [T]2 R24/25	T; N R: 10-20-24/25-36/37/38-43-65-50/53		

*Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.*

	(Z)-1,3-dichloropropene [2]				Xn; R20-65 Xi; R36/37/38 R43 N; R50-53	S: (1/2-)36/37-45-60-61		
602-054-00-6	iodpropene; allyl iodide		209-130-4556-56-9		F; R11 C; R34	F; C R: 11-34 S: (1/2-)7-16-26-45		
603-005-00-1	methylpropan-2-ol; tert-butyl alcohol		200-889-775-65-0		F; R11 Xn; R20 Xi; R36/37	F; Xn R: 11-20-36/37 S: (2-)9-16-46		
603-018-00-2	2-furyl alcohol		202-626-198-00-0		Carc. Cat. 3; R40 T; R23 Xn; R21/22-48/20-21 Xi; R36/37	T R: 21/22-23-36/37-40-48/20 S: (1/2-)36/37-45-63		
603-023-00-X	ethylene oxide; oxirane	E	200-849-975-21-8		F+; R12 R6 Carc. Cat. 2; R45 Muta. Cat. 2; R46 T; R23 Xi; R36/37/38	F+; T R: 45-46-6-12-23-36/37/38 S: 53-45		
603-029-00-3	1,2-(2-chloroethyl) ether		203-870-1111-44-4		Carc. Cat. 3; R40 T+; R26/27/28	T+ R: 26/27/28-40 S: (1/2-)7/9-27-28-36/37-45	C ≥ 7 %: T+; 1 % 7 %: T; R23/24/25-40 0,1 % ≤ C < 1 %: Xn; R20/21/22	
603-037-00-6	cellulose nitrate; nitrocellulose	T	—	—	E; R3	E R: 3 S: (2-)35		



*Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.*

603-046-00-5	bis(chloromethyl) ether; oxybis(chloromethane)	208-832-8542-88-1	F; R11 Carc. Cat. 1; R45 T+; R26 T; R24 Xn; R22	F; T+ R: 45-11-22-24-26 S: 53-45	C ≥ 25 %: R45-22-24-26 7 % ≤ C < 25 %: T+; R45-21-26 3 % ≤ C < 7 %: T; R45-21-23 1 % ≤ C < 3 %: T; R45-23 0,1 % ≤ C < 1 %: T; R45-20 0,001 % ≤ C < 0,1 %: T; R45
603-064-00-3	methoxy-2-propanol; monopropylene glycol methyl ether	203-539-1107-98-2	R10 R67	R: 10-67 S: (2-)	
603-066-00-2	4-epoxyethylcyclohexane; 4-vinylcyclohexene diepoxide	203-437-7106-87-6	Carc. Cat. 3; R40 T; R23/24/25	T R: 23/24/25-40 S: (1/2-)36/37-45-46	C ≥ 1 %: T; R23/24/25-40 0,1 % ≤ C < 1 %: Xn; R20/21/22
605-004-00-4	4,6-trimethyl-1,3,5-trioxane; paraldehyde	204-639-8123-63-7	R10	R: 10 S: (2-)29	
605-005-00-7	7,6,8-tetramethyl-1,3,5,7-tetraoxacyclooctane; metaldehyde	203-600-2108-62-3	F; R11 Xn; R22	F; Xn R: 11-22 S: (2-)13-16-25-46	
606-021-00-7	methyl-2-pyrrolidone;	212-828-1872-50-4	Repr. Cat. 2; R61	T R: 61-36/37/38 S: 53-45	C ≥ 10 %: T; R61-36/37/38

*Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.*

	1-methyl-2-pyrrolidone					Xi; R36/37/38		5 % ≤ C < 10 %: T; R61
607-007-00	Salts of oxalic acid with the exception of those specified elsewhere in this Annex	A	—	—		Xn; R21/22	Xn R: 21/22 S: (2-)24/25	C ≥ 5 %: Xn; R21/22
607-012-00	Benzoyl chloride		202-710-898-88-4			Xn; R20/21/22 C; R34 R43	C R: 20/21/22-34-43 S: (1/2-)26-36/37/39-45	
607-037-00	7-ethoxyethyl acetate; ethylglycol acetate	E	203-839-2111-15-9			R10 Repr. Cat. 2; R60-61 Xn; R20/21/22	T R: 60-61-10-20/21/22 S: 53-45	
607-051-00	MCPA (ISO); 4-chloro- <i>o</i> -tolylxyacetic acid		202-360-694-74-6			Xn; R22 Xi; R38-41 N; R50-53	Xn; N R: 22-38-41-50/53 S: (2-)26-37-39-60-61	
607-052-00	Salts and esters of MCPA	A	—	—		Xn; R20/21/22 N; R50-53	Xn; N R: 20/21/22-50/53 S: (2-)13-60-61	
607-085-00	Benzyl benzoate		204-402-9120-51-4			Xn; R22 N; R51-53	Xn; N R: 22-51/53 S: (2-)25-46-61	
607-095-00	Maleic acid		203-742-5110-16-7			Xn; R22 Xi; R36/37/38 R43	Xn R: 22-36/37/38-43 S: (2-)24-26-28-37-46	C ≥ 25 %: Xn; R22-36/37/38-43 ≤ C <25 %: Xi; R36/37/38-43

*Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.*

							0,1 % ≤ C < 20 %: Xi; R43
607-103-005	isocinnic anhydride		203-570-0108-30-5	Xn; R22 Xi; R36/37	Xn R: 22-36/37 S: (2-)25-46		C ≥ 5 %: Xn; R22-36/37 1 % ≤ C < 5 %: Xi; R36/37
607-142-008	n-propyl chloroformate; chloroformic acid propylester; n-propyl chloroformate		203-687-7109-61-5	F; R11 T; R23 C; R34	F; T R: 11-23-34 S: (1/2-)16-26-36-45		
607-195-007	methoxy-1-methylethyl acetate		203-603-9108-65-6	R10	R: 10 S: (2-)		
607-216-001 X	glutamic acid, reaction products with N-(C <sub>12-14</sub> -alkyl)propylenediamine		403-950-8—	T+; R26 Xn; R22 C; R34 N; R50	T+; N R: 22-26-34-50 S: (1/2-)26-36/37/39-38-45-61		
607-231-001	pyridalid (ISO); 3,6-dichloropyridine-2-carboxylic acid		216-935-41702-17-6	Xi; R41	Xi R: 41 S: (2-)26-39		
607-245-008	n-butyl acrylate	D	216-768-71663-39-4	F; R11 Xn; R20/21/22 Xi; R37/38 R43 N; R51-53	F; Xn; N R: 211-20/21/22-37/38-43-51/53 S: (2-)16-25-30-61	C ≥ 25 %: Xn; R20/21/22-37/38-43-51/53 30-61 ≤ C < 25 %: Xi; R37/38-43-52/53 2,5 % ≤ C < 20 %: Xi; R43-52/53	

*Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.*

						1 % ≤ C < 2,5 %: Xi; R43
607-397-00-5			415-930-6		Repr. Cat. 3; R62 R43	Xn R: 43-62 S: (2-)23-36/37
	mixture of: Ca salicylates (branched C <sub>10-14</sub> and C <sub>18-30</sub> alkylated); Ca phenates (branched C <sub>10-14</sub> and C <sub>18-30</sub> alkylated); Ca sulfurised phenates (branched C <sub>10-14</sub> and C <sub>18-30</sub> alkylated)					
608-005-00-5			203-700-6	109-74-0	F; R11 T; R23/24/25	F; T R: 11-23/24/25 S: (1/2-)16-36/37-45-63
	butyronitrile					
608-011-00-8			207-306-5	460-19-5	F+; R12 T; R23 N; R50-53	F+; T; N R: 12-23-50/53 S: (1/2-)9-16-23-33-45-63-60-61
	oxalonnitrile; cyanogen					
608-044-00-8			423-740-1	10461-98-0	Xn; R22 N; R51-53	Xn; N R: 22-51/53 S: (2-)46-61
	cyclohexylidene-2- phenylacetonitrile					
609-007-00-9	E		204-450-0	[2]-14-2	[C]hrc. Cat. [R]45 Muta. Cat. 3; R68 Repr. Cat. 3; R62	T; N R: 45-23/24/25-48/22-62-68-50/53 S: 53-45-60-61
	dinitrotoluene; [1] dinitrotoluene [2]		246-836-1	[2]-21-14-0		

*Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.*

					T; R23/24/25 Xn; R48/22 N; R50-53		
611-028-00	C,C'- azodi(formamide)		204-650-8	123-77-3	E; R2 R42	E; Xn R: 2-42 S: (2-)22-24-37	
611-035-00	Centralithium 6- amino-4- hydroxy-3- [7- sulfonato-4- (5- sulfonato-2- naphthylazo)-1- naphthylazo]naphthalene-2,7- disulfonate		403-660-1	107246-8	NO R51-53	N R: 51/53 S: 61	
612-044-00	N,N'- diacetylbenzidine	E	210-338-2	2613-35-4	Carc. Cat. 2; R45 Muta. Cat. 3; R68 Xn; R20/21/22	T R: 45-20/21/22-68 S: 53-45	
612-050-00	cyclohexylamine		203-629-0	108-91-8	R10 Repr. Cat. 3; R62 Xn; R21/22 C; R34	C R: 10-21/22-34-62 S: (1/2-)26-36/37-39-45 25 %: C; R34-62 5 % ≤ C < 10 %: Xn; R36/38-62 2 % ≤ C < 5 %: Xi; R36/38	
612-076-00	ethyl dimethylamine		209-940-8	598-56-1	F; R11 Xn; R20/22 C; R34	F; C R: 11-20/22-34 S: (1/2-)3-16-26-36-45	

*Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.*

612-099-00-3	E	202-453-195-80-7			Carc. Cat. 2; R45 Muta. Cat. 3; R68 Repr. Cat. 3; R62 T; R25 Xn; R21-48/22 R43 N; R51-53	T; N R: 45-21-25-43-48/22-62-68-51/53 S: 53-45-61		
612-101-00-2		202-905-8100-97-0			F; R11 R43	F; Xi R: 11-43 S: (2-)24-37		
612-151-00-6	E	—	—		Carc. Cat. 2; R45 Muta. Cat. 3; R68 Repr. Cat. 3; R62 T; R25 Xn; R21-48/22 Xi; R36 R43 N; R51-53	T; N R: 45-21-25-36-43-48/22-62-68-51/53 S: 53-45-61		
612-237-00-2		233-154-410046-00-1 244-077-020845-01-6 242-818-219098-16-9 258-872-514933-48-4			E; R2 Carc. Cat. 2; R45 Muta. Cat. 3; R68 Repr. Cat. 3; R62 T; R25 Xn; R21-48/22 Xi; R36 R43 N; R50	E; Xn; N R: 21/22-36/38-40-43-48/22-50 S: (2-)36/37-61		

**Status:** EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

613-116-00	007	fluorid (ISO); dichloro- <i>N</i> - [(dimethylamino)sulphonyl]fluoro- <i>N</i> - ( <i>p</i> - tolyl)methanesulphenamide; [containing ≥ 0,1 % (w/w) of particles with an aerodynamic diameter of below 50 µm]	211-986-9	731-27-1	T+; R26 T; R48/23 Xi; R36/37/38 R43 N; R50	T+; N R: 26-36/37/38-41 S: (1/2-)28-36/37/39-45-63-61	C ≥ 20 %: R26-36/37/38-43-48/23-50 R26-36/37/38-43-48/23-50 ≤ C < 20 %: T+, N; R26-43-48/23-50 7 % ≤ C < 10 %: T+, N; R26-43-48/20-50 2,5 % ≤ C < 7 %: T, N; R23-43-48/20-50 1 % ≤ C < 2,5 %: T; R23-43-48/20 0,1 % ≤ C < 1 %: Xn; R20	
615-001-00	007	ethyl isocyanate	210-866-3	624-83-9	F; R11 Repr. Cat. 3; R63 T+; R26 T; R24/25 R42/43 Xi; R37/38-41	F; T+ R: 11-24/25-26-37/38-41-42/43-63 S: (1/2-)16-26-27/28-36/37/39-45-63		
615-004-00	008	Salts of A thiocyanic acid, with the exception of those specified elsewhere in this Annex	—	—	Xn; R20/21/22 R32 R52-53	Xn R: 20/21/22-32-52/53 S: (2-)13-36/37-46-61		
615-028-00	004	ethyl 2- (isocyanatosulfonyl)benzoate	410-220-2	77375-79	R14 Xn; R22-48/22 Xi; R41 R42/43	Xn R: 14-22-41-42/43-48/22 S: (2-)8-23-26-30-35-36/37/39		

*Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.*

615-030-00	Alkali salts and alkali earth salts of thiocyanic acid, with the exception of those specified elsewhere in this Annex	A	—	—	Xn; R20/21/22 R32 R52-53	Xn R: 20/21/22-32-52/53 S: (2-)13-36/37-46-61		
615-031-00	Potassium thiocyanate		222-571-73535-84-0		T+; R26/28 Xn; R21 R32 R33 N; R51-53	T+; N R: 21-26/28-32-33-51/53 S: (1/2-)13-28-36/37-45-61		
615-032-00	Metal salts of thiocyanic acid, with the exception of those specified elsewhere in this Annex	A	—	—	Xn; R20/21/22 R32 N; R50-53	Xn; N R: 20/21/22-32-50/53 S: (2-)13-36/37-46-60-61		
616-124-00	Titium bis(trifluoromethylsulfonyl)imide		415-300-090076-65		T; R24/25 Xn; R48/22 C; R34 R52-53	T R: 24/25-34-48/22-52/53 S: (1/2-)22-26-36/37/39-45-61		
617-017-00 X	A mixture of: 2,2'-bis( <i>tert</i> -pentylperoxy)- <i>p</i> -diisopropylbenzene; 2,2'-bis( <i>tert</i> -pentylperoxy)- <i>m</i> -diisopropylbenzene	T	412-140-332144-25		E; R2 O; R7 R53	E R: 2-7-53 S: (2-)3/7-14-36/37/39-61		
650-016-00	Mineral wool,	AQR	—	—	Carc. Cat. 3; R40	Xn R: 40		



*Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.*

	with the exception of those specified elsewhere in this Annex; [Man-made vitreous (silicate) fibres with random orientation with alkaline oxide and alkali earth oxide (Na <sub>2</sub> O +K <sub>2</sub> O +CaO +MgO +BaO) content greater than 18 % by weight]				S: (2-)36/37	
650-017-00	Refractory Ceramic Fibres, Special Purpose Fibres, with the exception of those specified elsewhere in this Annex; [Man-made vitreous (silicate) fibres with random	AR	—	—	Carc. Cat. 2; R49 T R: 49 S: 53-45	

*Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.*

orientation with alkaline oxide and alkali earth oxide (Na <sub>2</sub> O +K <sub>2</sub> O +CaO + MgO +BaO) content less or equal to 18 % by weight]							
---	--	--	--	--	--	--	--

## ANNEX 1B

Index No	Chemical name	Notes related to substances	EC No	CAS No	Classification	Labelling	Concentration Limits	Notes related to preparations
003-003-0025	methylpropyl)lithium; isobutyllithium		440-620-2920-36-5	2920-36-5	F; R15-17 R14 C; R35 R67 N; R50-53	F; C; N R: 14/15-17-35-67-50/53 S: (1/2-)6-16-26-30-33-36/37/39-43-45-60-61		
005-013-0016	dimethylmethoxyborane		425-380-97397-46-8	97397-46-8	F; R17 Xn; R20/21/22-48/22-53 C; R34 R43 R53	F; C R: 14/15-17-35-67-50/53 S: (1/2-)6-16-26-30-33-36/37/39-43-45-61		
005-014-0010	formylphenylboronic acid		438-670-587199-17	587199-17	R43	Xi R: 43 S: (2-)24-37		
005-017-0007	sodium perborate; perboric acid, sodium salt; [2]	E [1]	239-172-91120-21-0 234-390-012138-47-9 - [3] 12040-72-1 231-556-47432-04-4 - [5] 10332-33-9	1120-21-0 12138-47-9 12040-72-1 1432-04-4 10332-33-9	O; T R: 61-8-22-37-41-62 S: 53-45	O; T R: 61-8-22-37-41-62 S: 53-45	C ≥ 25 %: T; 22 % ≤ C <	

*Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.*

								perboric acid, sodium salt, monohydrate; [3] sodium peroxometaborate; [4] perboric acid (HBO(O <sub>2</sub> )), sodium salt, monohydrate; [5] sodium peroxoborate; [containing < 0,1 % (w/w) of particles with an aerodynamic diameter of below 50 µm]				Repr. Cat. 3; R62 Xn; R22 Xi; R37-41		25 %: T; R61-37-41-62 20 % ≤ C < 22 %: T; R61-36/37-62 14 % ≤ C < 20 %: T; R61-36-62 9 % ≤ C < 14 %: T; R61-62 6,5 % ≤ C < 9 %: T; R61
005-017-01	E	239-172-9 [1] 234-390-0 [2] - [3] 231-556-4 [4] - [5]	120-21-0 [1] 138-47-9 [2] 12040-72-1 [3] 12-04-4 [4] 10332-33-5 [5]	Repr. Cat. 3; R62 T; R23 Xn; R22 Xi; R37-41	O; T R: 61-8-22-2 S: 53-45	C ≥ 25 %: T; R61-41-62 22 % ≤ C < 25 %: T; R61-20-37-41-62 20 % ≤ C < 22 %: T; R61-20-36/37-62 14 % ≤ C < 20 %: T; R61-20-36-62 9 % ≤ C < 14 %: T; R61-20-62 6,5 % ≤ C < 9 %: T; R61-20 3 % ≤ C < 6,5 %: Xn; R20								

*Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.*

	of below 50 µm]						
005-018-002	perboric acid (H3BO2(O2)), monosodium salt trihydrate; [1] perboric acid, sodium salt, tetrahydrate; [2] perboric acid (HBO(O2)), sodium salt, tetrahydrate; [3] sodium peroxoborate hexahydrate; [containing < 0,1 % (w/w) of particles with an aerodynamic diameter of below 50 µm]		- [1] - [2] - [3]	13517-20-001 37244-98-001 10486-00-001	Repr. Cat. 2; R61 Repr. Cat. 3; R62 Xi; R37-41	T R: 61-37-41-62 S: 53-45-47	C ≥ 36 %: T; 61-37-41-62 22 % ≤ C < 36 %: T; R61-36/37-62 20 % ≤ C < 22 %: T; R61-37-62 14 % ≤ C < 20 %: T; R61-62 10 % ≤ C < 14 %: T; R61
005-018-001 X	perboric acid (H3BO2(O2)), monosodium salt, trihydrate; [1] perboric acid, sodium salt, tetrahydrate; [2] perboric acid (HBO(O2)), sodium salt, tetrahydrate; [3] sodium peroxoborate hexahydrate;	E	- [1] - [2] - [3]	13517-20-001 37244-98-001 10486-00-001	Repr. Cat. 2; R61 Repr. Cat. 3; R62 Xn; R20 Xi; R37-41	T R: 61-20-37-41-62 S: 53-45-47	C ≥ 36 %: T; 61-20-37-41-62 25 % ≤ C < 36 %: T; R61-20-36/37-62 22 % ≤ C < 25 %: T; R61-36/37-62 20 % ≤ C < 22 %: T; R61-37-62 14 % ≤ C < 20 %: T; R61-62 10 % ≤ C <

**Status:** EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

	[containing ≥ 0,1 % (w/w) of particles with an aerodynamic diameter of below 50 µm]					14 %: T; R61	
006-097-00-6	phenyl-3-( <i>p</i> -toluenesulfonyl)urea	424-620-1	13909-63	Xn; R22-48/22 R52-53	Xn R: 22-48/22-52/53 S: (2-)22-36-61		
006-098-00-7	tert-butyl (1 <i>R</i> ,5 <i>S</i> )-3-azabicyclo[3.1.0]hex-6-ylcarbamate	429-170-8	134575-1	Xn; R22-48/22 Xi; R41 R43	Xn R: 22-41-43-48/22 S: (2-)22-26-36/37/39		
006-099-00-7	<i>p</i> -toluenesulfonyl)- <i>N</i> '-(3-( <i>p</i> -toluenesulfonyloxy)phenyl)urea; 3-({[4-methylphenyl)sulfonyl]carbamoyl} amino)phenyl 4-methylbenzenesulfonate	432-520-2	232938-4	N; R51-53	N R: 51/53 S: 22-61		
006-101-00-6	mixture of: <i>N,N</i> '-(methylenedi-4,1-phenylene)bis[ <i>N</i> '-phenylurea]; <i>N</i> -(4-[[4-[(phenylamino)carbonyl]amino]phenylmethyl]phenyl)- <i>N</i> '-cyclohexylurea; <i>N,N</i> '-(methylenedi-4,1-phenylene)bis[ <i>N</i> '-cyclohexylurea]	423-070-8	—	R53	R: 53 S: 61		
006-102-00-4	hexyl- <i>N</i> -ethoxycarbonylthiocarbamate	432-750-3	—	Carc. Cat. 2; R45 Muta. Cat. 2; R46	T; N R: 45-46-22-43-48/22-51/53 S: 53-45-61		

*Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.*

				Xn; R22-48/22 R43 N; R51-53			
006-103-00	<i>N,N'</i> - (methylenedi-4,1- phenylene)bis[ <i>N'</i> - octyl]urea	445-760-8		Xi; R41 R42 N; R50-53	Xn; N R: 41-42-50/53 S: (2-)22-26-39/45-60-61	C ≥ 10 %: Xn, N; R41-42-50/53 < 10 %: Xn, N; R36-42-50/53 1 % ≤ C < 5 %: Xn, N; R42-50/53 0,25 % ≤ C < 1 %: N; R50/53 0,025 % ≤ C < 0,25 %: N; R51/53 0,0025 ≤ C < 0,025 %: R52/53	
007-029-00	Diethyldimethylammonium hydroxide	419-400-5	500-19	Xn; R21/22 C; R35	C R: 21/22-35 S: (1/2-)26-36/37/39-45		
012-004-00 X	Aluminium- magnesium- carbonate- hydroxide- perchlorate- hydrate	422-150-1		N; R50-53	N R: 50/53 S: 60-61		
014-036-00 X	(4- ethoxyphenyl) (3-(4- fluoro-3- phenoxyphenyl)propyl)dimethylsilane	405-020-7	105024-66	Repr.Cat.2 R60 N; R50-53	T; N R: 60-50/53 S: 53-45-60-61	C ≥ 0,5 %: T, N; R60-50/53 0,025 % ≤ C < 0,5 %: N; R50/53	

**Status:** EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

						0,0025 % ≤ C < 0,025 %: N; R51/53 0,00025 % ≤ C < 0,0025 %: R52/53
014-037-00-5	butanone- <i>O,O</i> ' <i>O</i> '- (phenylsilylidene)trioxime	433-360-634036-80		Xn; R48/22 R43 R52-53	Xn R: 43-48/22-52/53 S: (2-)36/37-61	
014-038-00-03-	(triethoxysilyl)propyl)octanethioate	436-690-9220727-26		R43	Xi R: 43 S: (2-)24-37	
014-039-00-26-	dimethylbut-2- yl)- trimethoxysilane	439-360-2142877-45		Xi; R38-41 R52-53	Xi R: 38-41-52/53 S: (2-)26-37/39-61	
014-041-00-7-	bis(trimethylsilyl)aminopropylmethyl-diethylsilane	445-890-5201290-01		Xn; R22 R43	Xn R: 22-43 S: (2-)24-37	
014-042-00-02-	mixture of: <i>O,O</i> ' <i>O</i> '', <i>O</i> '''- silanetetrayl tetrakis(4- methyl-2- pentanone oxime) (3 stereoisomers)	423-010-0—		Xi; R41	Xi R: 41 S: (2-)26-39	
014-043-00-08-	reaction product of amorphous silica (50-85 %), butyl (1- methylpropyl) magnesium (3-15 %), tetraethyl orthosilicate (5-15 %)	432-200-2—		F; R11 Xi; R37/38-41 R52-53	F; Xi R: 11-37/38-41-52/53 S: (2-)6-26-36/39-61	

*Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.*

	and titanium tetrachloride (5-20 %)						
014-044-00-1	(4'-acetoxy-3'-methoxyphenyl)propyl]trimethoxysilane	433-050-0			N; R51-53	N R: 51/53 S: 61	
014-045-00-9	magnesium sodium fluoride silicate	442-650-1			Xn; R48/20	Xn R: 48/20 S: (2-)22-36	
015-190-00-6	(2,4-dicumylphenyl)neopentyl diphosphite; 3,9-bis[2,4-bis(1-methyl-1-phenylethyl)phenoxy]-2,4,8,10-tetraoxa-3,9-diphosphaspiro[5.5]undecane	421-920-2	154862-4	3853		R: 53 S: 61	
015-191-00-6	decyldiphenyl phosphate	431-760-5	27460-02		Xi; R38 R52-53	Xi R: 38-52/53 S: (2-)37-61	
015-192-00-1	tetrakis(2,6-dimethylphenyl)- <i>m</i> -phenylene biphosphate	432-770-2	139189-30	313	R33 R53	Xi R: 43-53 S: (2-)24-37-61	
015-193-00-7	(phenyl(phenylmethyl)1,1,2,2,3,3,4,4,4-nonafluoro- <i>N</i> -methyl-1-butanesulfonamide (1:1)	442-960-7	33235-9	313	R25 Xi; R41 N; R50-53	T; N R: 25-41-50/53 S: (1/2-)26-39-45-60-61	
015-194-00-2	tert-butylphosphonium nonafluorobutane-1-sulfonate	444-440-5	220689-12		Xn; R22 R52-53	Xn R: 22-52/53 S: (2-)61	
015-195-00-8	mixture of: potassium <i>o</i> -toluenephosphonate;	433-860-4			Xi; R36 R43 R52-53	Xi R: 36-43-52/53 S: (2-)24-26-37-61	



*Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.*

	potassium <i>m</i> - toluenephosphonate; potassium <i>p</i> - toluenephosphonate						
015-196-001	Mixture of: dimethyl (2- (hydroxymethylcarbamoyl)ethyl)phosphonate; diethyl (2- (hydroxymethylcarbamoyl)ethyl)phosphonate; methyl ethyl (2- (hydroxymethylcarbamoyl)ethyl)phosphonate	435-960-3	—	Carc. Cat. 2 R45 Muta. Cat. 2 R46 R43;	T R: 25-46-43 S: 53-45		
015-197-001	(2,4,4- trimethylpentyl)dithiophosphonic acid	420-160-9	107667-02	R10 T; R23 Xn; R22 C; R34 N; R51-53	T; N R: 10-22-23-34-51/53 S: (1/2-)9-26-36/37/39-45-61		
015-198-004	(4- phenylbutyl)phosphinic acid	420-450-5	86552-32	Carc. Cat. 3 R40 Xi; R41	Xn R: 40-41 S: (2-)23-26-36/37/39		
016-094-000	Sulfur	231-722-6	7704-34-9	Xi; R38	Xi R: 38 S: (2-)46		
016-097-008	2-amino-2- methyl-2- propanethiol hydrochloride	434-480-1	32047-53	Xn; R22 C; R34 R43 R52-53	C R: 22-34-43-52/53 S: (1/2-)22-26-36/37/39-45-61		
017-009-018	Ammonium perchlorate; [containing < 80 % of 0-30 µm particles]	232-235-1	7790-98-9	E; R2 O; R9	E R: 2-9 S: (2-)14-16-36/37		
022-004-000	Potassium titanium oxide (K <sub>2</sub> Ti <sub>6</sub> O <sub>13</sub> )	432-240-0	12056-51	Carc. Cat. 3 R40	Xn R: 40 S: (2-)22-36/37		
022-005-007	(1,1- dimethylethyl)-1,1-	419-840-8	169104-7	IF R11 C; R34	F; C		

*Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.*

	dimethyl-1-[(1,2,3,4,5-η)-2,3,4,5-tetramethyl-2,4-cyclopentadien-1-yl]silanaminato(2-)-κN[(1,2,3,4-η)-1,3-pentadiene]-titanium				R43 R53	R: 11-34-43-53 S: (1/2-)6-9-16-26-36/37/39-45-61	
028-002-001	Nickel powder; [particle diameter < 1 mm]		231-111-4	7440-02-0	Carc. Cat. 3; R40 T; R48/23 R43 R52-53	T R: 40-43-48/23-52/53 S: (2-)36/37/39-45-61	
028-013-001	Nickel matte	E, H	273-749-6	69012-50	Carc. Cat. 1; R49 T; R48/23 R43 N; R50-53	T; N R: 49-43-48/23-50/53 S: 53-45-60-61	
028-014-001	Slimes and sludges, copper electrolytic refining, decopperised, nickel sulfate	E	295-859-3	92129-57	Carc. Cat. 1; R49 Muta. Cat. 3; R68 Repr. Cat. 2; R61 T; R48/23 Xn; R20/22 Xi; R38 R42/43 N; R50-53	T; N R: 49-61-20/22-38-42/43-48/23-68-50/53 S: 53-45-60-61 C ≥ 25 %: R49-61-20/22-38-42/43-48/23-68-50/53 C < 25 %: 25 %: T, N; R49-61-38-42/43-48/23-68-51/53 2,5 %: C < 20 %: 20 %: T, N; R49-61-42/43-48/23-68-51/53 1 % ≤ C < 2,5 %: T; R49-61-42/43-48/23-68-52/53 0,5 %: C < 1 %: T; R49-61-43-48/20-52/53 0,25 %: C < 0,5 %: T; R49-43-48/20-52/53	

**Status:** EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

						0,1 % ≤ C < 0,25 %: T; R49-43-48/20 0,01 % ≤ C < 0,1 %: Xi; R43	
028-015-0018	Slimes and sludges, copper electrolyte refining, decopperised	E, H	305-433-1	94551-87-6	Carc. Cat. 1; R49 Muta. Cat. 3; R68 Repr. Cat. 1; R61 Repr. Cat. 3; R62 T; R48/23 R42/43 N; R50-53	T; N R: 49-61-42/43-48/23-62-68-50/53 S: 53-45-60-61	
028-016-0013	Nickel diperchlorate; perchloric acid, nickel(II) salt	E, H	237-124-1	113637-71-6	Carc. Cat. 1; R49 Muta. Cat. 3; R68 Repr. Cat. 2; R61 T; R48/23 C; R34 R42/43 N; R50-53	T; N R: 49-61-34-42/43-48/23-68-50/53 S: 53-45-60-61 C ≥ 25 %: R49-61-34-42/43-48/23-68-50/53 C < 25 %: T, N; R49-61-34-42/43-48/23-68-51/53 2,5 % ≤ C < 5 %: T, N; R49-61-36/38-42/43-48/23-68-51/53 1 % ≤ C < 2,5 %: T; R49-61-36/38-42/43-48/23-68-52/53 0,5 % ≤ C < 1 %: T; R49-61-43-48/20-52/53 0,25 % ≤ C < 0,5 %: T; R49-43-48/20-52/53 0,1 % ≤ C <	

*Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After*

*IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.*

							0,25 %: T; R49-43-48/20 0,01 % ≤ C < 0,1 %: Xi; R43
028-017-0010	nickel dipotassium bis(sulfate); [1] diammonium nickel bis(sulfate) [2]	E, H	237-563-9 [13842-46-0]; 239-793-2 [2699-18-0]	Carc. Cat. 1; R49 Muta. Cat. 3; R68 Repr. Cat. 2; R61 T; R48/23 Xn; R20/22 R42/43 N; R50-53	T; N R: 49-61-20/22-42/43-48/23-68-50/53 S: 53-45-60-02,5 %	C ≥ 25 %: R49-61-20/22-42/43-48/23-68-50/53 0,5 % ≤ C < 25 %: T, N; R49-61-42/43-48/23-68-51/53 1 % ≤ C < 2,5 %: T; R49-61-42/43-48/23-68-52/53 0,5 % ≤ C < 1 %: T; R49-61-43-48/20-52/53 0,25 % ≤ C < 0,5 %: T; R49-43-48/20-52/53 0,1 % ≤ C < 0,25 %: T; R49-43-48/20	
028-018-0011	nickel bis(sulfamidate); nickel sulfamate	E, H	237-396-1 [13770-89-5]	Carc. Cat. 1; R49 Muta. Cat. 3; R68 Repr. Cat. 2; R61 T; R48/23 R42/43 N; R50-53	T; N R: 49-61-42/43-48/23-68-50/53 S: 53-45-60-02,5 %	C ≥ 25 %: R49-61-42/43-48/23-68-50/53 0,5 % ≤ C < 25 %: T, N; R49-61-42/43-48/23-68-51/53 1 % ≤ C < 2,5 %: T; R49-61-42/43-48/23-68-52/53	

*Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.*

						0,5 % ≤ C < 1 %: T; R49-61-43-48/20-52/53 0,25 % ≤ C < 0,5 %: T; R49-43-48/20-52/53 0,1 % ≤ C < 0,25 %: T; R49-43-48/20 0,01 % ≤ C < 0,1 %: Xi; R43	
028-019-001 X	Nickel bis(tetrafluoroborate)	E, H	238-753-4 14708-14	Carc. Cat. 1; R49 Muta. Cat. 3; R68 Repr. Cat. 2; R61 T; R48/23 R42/43 N; R50-53	T; N R: 49-61-42/43-48/23-68-50/53 S: 53-45-60-01,5 %	C ≥ 25 %: R49-61-42/43-48/23-68-50/53 0,5 % ≤ C < 25 %: T, N; R49-61-42/43-48/23-68-51/53 1 % ≤ C < 2,5 %: T; R49-61-42/43-48/23-68-52/53 0,5 % ≤ C < 1 %: T; 49-61-43-48/20-52/53 0,25 % ≤ C < 0,5 %: T; R49-43-48/20-52/53 0,1 % ≤ C < 0,25 %: T; R49-43-48/20 0,01 % ≤ C < 0,1 %: Xi; R43	
028-021-001	Nickel diformate; [1]	E, H	222-101-03 349-06-2 239-946-6 [2] 343-02-4 [3] 268-755-06 34-59-8 [3]	Carc. Cat. 1; R49	T; N R: 49-61-42/43-48/23-68-50/53	C ≥ 25 %: R49-61-42/43-48/23-68-50/53	

*Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After*

*IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.*

					Muta. Cat. 3; R68 Repr. Cat. 2; R61 T; R48/23 R42/43 N; R50-53	S: 53-45-60- <del>61</del>	T, N; R49-61-42/43-48/23-68-50/53 2,5 % C < 25 %: T, N; R49-61-42/43-48/23-68-51/53 1 % ≤ C < 2,5%: T; R49-61-42/43-48/23-68-52/53 0,5 % ≤ C < 1 %: T; R49-61-43-48/20-52/53 0,25 % ≤ C < 0,5 %: T; R49-43-48/20-52/53 0,1 % ≤ C < 0,25 %: T; R49-43-48/20 0,01 % ≤ C 0,1 %: Xi; R43
028-022-0016	nickel di(acetate); [1] nickel acetate [2]	E, H	206-761-7373-02-4 239-086-11298-37	[Chrc. Cat. 9; R49 Muta. Cat. 3; R68 Repr. Cat. 2; R61 T; R48/23 Xn; R20/22 R42/43 N; R50-53	T; N R: 49-61-20/22-42/43-48/23-68-50/53 S: 53-45-60- <del>61</del>	C ≥ 25 %: R49-61-20/22-42/43-48/23-68-50/53 R49-61-20/22-42/43-48/23-68-50/53 2,5 % ≤ C < 25 %: T, N: R49-61-42/43-48/23-68-51/53 1 % ≤ C < 2,5 %: T; R49-61-42/43-48/23-68-52/53 0,5 % ≤ C < 1 %: T; R49-61-43-48/20-52/53 0,25 % ≤ C 0,5 %: T; R49-43-48/20-52/53 0,1 % ≤ C <	

*Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.*

						0,25 %: T; R49-43-48/20 0,01 % ≤ C < 0,1 %: Xi; R43
028-024-0017	nikel dibenzoate	E, H	209-046-8553-71-9	Carc. Cat. 1; R49 Muta. Cat. 3; R68 Repr. Cat. 2; R61 T; R48/23 R42/43 N; R50-53	T; N R: 49-61-42/43-48/23-68-50/53 S: 53-45-60-02,5 %	C ≥ 25 %: R49-61-42/43-48/23-68-50/53 0,5 % ≤ C < 25 %: T, N; R49-61-42/43-48/23-68-51/53 1 % ≤ C < 2,5 %: T; R49-61-42/43-48/23-68-52/53 0,5 % ≤ C < 1 %: T; R49-61-43-48/20-52/53 0,25 % ≤ C < 0,5 %: T; R49-43-48/20-52/53 0,1 % ≤ C < 0,25 %: T; R49-43-48/20
028-025-0012	nikel bis(4- cyclohexylbutyrate)	E, H	223-463-23906-55-6	Carc. Cat. 1; R49 Muta. Cat. 3; R68 Repr. Cat. 2; R61 T; R48/23 R42/43 N; R50-53	T; N R: 49-61-42/43-48/23-68-50/53 S: 53-45-60-02,5 %	C ≥ 25 %: R49-61-42/43-48/23-68-50/53 0,5 % ≤ C < 25 %: T, N; R49-61-42/43-48/23-68-51/53 1 % ≤ C < 2,5 %: T; R49-61-42/43-48/23-68-52/53

*Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.*

							0,5 % ≤ C < 1 %: T; R49-61-43-48/20-52/53 0,25 % ≤ C < 0,5 %: T; R49-43-48/20-52/53 0,1 % ≤ C < 0,25 %: T; R49-43-48/20 0,01 % ≤ C < 0,1 %: Xi; R43	
028-026-0018	nickel(II) stearate; nickel(II) octadecanoate	E, H	218-744-1	2223-95-2	Carc. Cat. 1; R49 Muta. Cat. 3; R68 Repr. Cat. 2; R61 T; R48/23 R42/43 N; R50-53	T; N R: 49-61-42/43-48/23-68-50/53 S: 53-45-60-01,5 %	C ≥ 25 %: R49-61-42/43-48/23-68-50/53 0,5 % ≤ C < 25 %: T, N; R49-61-42/43-48/23-68-51/53 1 % ≤ C < 2,5 %: T; R49-61-42/43-48/23-68-52/53 0,5 % ≤ C < 1 %: T; R49-61-43-48/20-52/53 0,25 % ≤ C < 0,5 %: T; R49-43-48/20-52/53 0,1 % ≤ C < 0,25 %: T; R49-43-48/20 0,01 % ≤ C < 0,1 %: Xi; R43	
028-027-0018	nickel dilactate	E, H	—	16039-61-6	Carc. Cat. 1; R49	T; N R: 49-61-42/43-48/23-68-50/53	C ≥ 25 %: R49-61-42/43-48/23-68-50/53	



**Status:** EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

					Muta. Cat. 3; R68 Repr. Cat. 2; R61 T; R48/23 R42/43 N; R50-53	S: 53-45-60- <del>61</del>	T, N; R49-61-42/43-48/23-68-50/53 2,5 % ≤ C < 25 %: T, N; R49-61-42/43-48/23-68-51/53 1 % ≤ C < 2,5 %: T; R49-61-42/43-48/23-68-52/53 0,5 % ≤ C < 1 %: T; R49-61-43-48/20-52/53 0,25 % ≤ C < 0,5 %: T; R49-43-48/20-52/53 0,1 % ≤ C < 0,25 %: T; R49-43-48/20 0,01 % ≤ C < 0,1 %: Xi; R43	
028-028-0010	nickel(II) octanoate	E, H	225-656-74995-91-9		Carc. Cat. 1; R49 Muta. Cat. 3; R68 Repr. Cat 2; R61 T; R48/23 C; R35 R42/43 N; R50-53	T; C; N R: 49-61-35-42/43-48/23-68-50/53 S: 53-45-60- <del>61</del>	C ≥ 25 %: R49-61-35-42/43-48/23-68-50/53 R49-61-35-42/43-48/23-68-50/53 10 % ≤ C < 25 %: T, C, N; R49-61-35-42/43-48/23-68-51/53 5 % ≤ C < 10 %: T, N; R49-61-34-42/43-48/23-68-51/53 2,5 % ≤ C < 5 %: T, N; R49-61-36/38-42/43-48/23-68-51/53 1 % ≤ C < 2,5 %: T; R49-61-36/38-42/43-48/23-68-52/53 0,5 % ≤ C <	

**Status:** EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

							1 %: T; R49-61-43-48/20-52/53 0,25 % ≤ C < 0,5 %: T; R49-43-48/20-52/53 0,1 % ≤ C < 0,25 %: T; R49-43-48/20 0,01 % ≤ C < 0,1 %: Xi; R43	
028-029-00	nickel difluoride; [1] nickel dibromide; [2] nickel diiodide; [3] nickel potassium fluoride [4]	E, H	233-071-3 [0028-18-01] 236-665-0 [2462-88-9] 236-666-6 [3462-90-1] - [4] 11132-10-8	028-18-01 2462-88-9 3462-90-1	Carc. Cat. 1; R49 Muta. Cat. 3; R68 Repr. Cat. 2; R61 T; R48/23 R42/43 N; R50-53	T; N R: 49-61-42/43-48/23-68-50/53 S: 53-45-60-61	C ≥ 25 %: R49-61-42/43-48/23-68-50/53 0,5 % ≤ C < 25 %: T, N; R49-61-42/43-48/23-68-51/53 1 % ≤ C < 2,5 %: T; 49-61-42/43-48/23-68-52/53 0,5 % ≤ C < 1 %: T; R49-61-43-48/20-52/53 0,25 % ≤ C < 0,5 %: T; 49-43-48/20-52/53 0,1 % ≤ C < 0,25 %: T; R49-43-48/20 0,01 % ≤ C < 0,1 %: Xi; R43	
028-030-00 X	nickel hexafluorosilicate	E, H	247-430-7 26043-11-8	26043-11-8	Carc. Cat. 1; R49 Muta. Cat. 3; R68	T; N R: 49-61-42/43-48/23-68-50/53 S: 53-45-60-61	C ≥ 25 %: R49-61-42/43-48/23-68-50/53 R49-61-42/43-48/23-68-50/53 61	

**Status:** EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

					Repr. Cat. 2; R61 T; R48/23 R42/43 N; R50-53		2,5 % ≤ C < 25 %: T, N; R49-61-42/43-48/23-68-51/53 1 % ≤ C < 2,5 %: T; R49-61-42/43-48/23-68-52/53 0,5 % ≤ C < 1 %: T; R49-61-43-48/20-52/53 0,25 % ≤ C < 0,5 %: T; R49-43-48/20-52/53 0,1 % ≤ C < 0,25 %: T; R49-43-48/20 0,01 % ≤ C < 0,1 %: Xi; R43	
028-031-0016	nickel selenate	E, H	239-125-215060-62	62	Carc. Cat. 1; R49 Muta. Cat. 3; R68 Repr. Cat. 2; R61 T; R48/23 R42/43 N; R50-53	T; N R: 49-61-42/43-48/23-68-50/53 S: 53-45-60-01,5 %	C ≥ 25 %: R49-61-42/43-48/23-68-50/53 R49-61-42/43-48/23-68-50/53 0,5 % ≤ C < 25 %: T, N; R49-61-42/43-48/23-68-51/53 1 % ≤ C < 2,5 %: T; R49-61-42/43-48/23-68-52/53 0,5 % ≤ C < 1 %: T; R49-61-43-48/20-52/53 0,25 % ≤ C < 0,5 %: T; R49-43-48/20-52/53 0,1 % ≤ C < 0,25 %:	

*Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.*

						T; R49-43-48/20 0,01 % ≤ C < 0,1 %: Xi; R43	
028-032-0010	nickel hydrogen phosphate; [1] nickel bis(dihydrogen phosphate); [2] trinickel bis(orthophosphate); [1] dinickel diphosphate; [4] nickel bis(phosphinate); [5] nickel phosphinate; [6] phosphoric acid, calcium nickel salt; [7] diphosphoric acid, nickel(II) salt [8]	E, H	238-278-2 [4] 242-522-3 [8] 233-844-5 [0] 238-426-6 [4] 238-511-8 [4] 252-840-4 [6] - [7] - [1] -	332-34-4 718-11-1 381-36-9 448-18-4 507-36-4 6026-88-7 17169-61-8 19372-20-4	Carc. Cat. 1; R49 T; R48/23 R42/43 N; R50-53	T; N R: 49-42/43-48/23-50/53 S: 53-45-60-61	
028-033-0016	ammonium nickel hexacyanoferrate	E, H	—	74195-78-	Carc. Cat. 1; R49 T; R48/23 R42/43 N; R50-53	T; N R: 49-42/43-48/23-50/53 S: 53-45-60-61	
028-034-0011	nickel dicyanide	E, H	209-160-8	557-19-7	Carc. Cat. 1; R49 T; R48/23 R42/43 R32 N; R50-53	T; N R: 49-32-42/43-48/23-50/53 S: 53-45-60-61	
028-035-0017	nickel chromate	E, H	238-766-5	14721-18-	Carc. Cat. 1; R49 T; R48/23 R42/43	T; N R: 49-42/43-48/23-50/53 S: 53-45-60-61	

*Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.*

					N; R50-53		
028-036-00	nickel(II) silicate; [1] dinickel orthosilicate; [2] nickel silicate (3:4); [3] silicic acid, nickel salt; [4] trihydrogen hydroxybis[orthosilicato(4-)]trinicke(3-) [5]	E, H	244-578-411784-78 237-411-113775-54-7; 250-788-733748-25-1; 253-461-737321-15-648; 235-688-33319-85-643	244-578-411784-78 237-411-113775-54-7; 250-788-733748-25-1; 253-461-737321-15-648; 235-688-33319-85-643	Carc. Cat. 1; R49 T; R48/23 R43 N; R50-53	T; N R: 49-43-48/23-50/53 S: 53-45-60-61	
028-037-00	nickel hexacyanoferrate	E, H	238-946-314874-78	238-946-314874-78	Carc. Cat. 1; R49 T; R48/23 R43 N; R50-53	T; N R: 49-43-48/23-50/53 S: 53-45-60-61	
028-038-00	nickel bis(arsenate); nickel(II) arsenate	E, H	236-771-713477-70	236-771-713477-70	Carc. Cat. 1; R45 T; R48/23 R43 N; R50-53	T; N R: 45-43-48/23-50/53 S: 53-45-60-61	
028-039-00	nickel oxalate; [1] oxalic acid, nickel salt [2]	E, H	208-933-7547-67-1 243-867-220543-06	208-933-7547-67-1 243-867-220543-06	Carc. Cat. 1; R49 T; R48/23 R43 N; R50-53	T; N R: 49-43-48/23-50/53 S: 53-45-60-61	
028-040-00	nickel telluride	E, H	235-260-612142-88	235-260-612142-88	Carc. Cat. 1; R49 T; R48/23 R43 N; R50-53	T; N R: 49-43-48/23-50/53 S: 53-45-60-61	
028-041-00 X	nickel tetrasulfide	E, H	—	12137-12	Carc. Cat. 1; R49 T; R48/23 R43	T; N R: 49-43-48/23-50/53 S: 53-45-60-61	

*Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.*

					N; R50-53			
028-042-0015	Nickel bis(arsenite)	E, H	—	74646-29	Carc. Cat. 1; R49 T; R48/23 R43 N; R50-53	T; N R: 49-43-48/23-50/53 S: 53-45-60-61		
028-043-0060	Cobalt nickel gray periclase; C.I. Pigment Black 25; C.I. 77332; [1] cobalt nickel dioxide; [2] cobalt nickel oxide [3]	E, H	269-051-648 261-346-818 - [3]	86-89-01 87-91-45-01 12737-30	Carc. Cat. 1; R49 T [3] R48/23 R43	T R: 49-43-48/23 S: 53-45		
028-044-0016	Nickel tin trioxide; nickel stannate	E, H	234-824-91	12035-38	Carc. Cat. 1; R49 T; R48/23 R43	T R: 49-43-48/23 S: 53-45		
028-045-0017	Nickel triuranium decaoxide	E, H	239-876-61	15780-33	Carc. Cat. 1; R49 T; R48/23 R43	T R: 49-43-48/23 S: 53-45		
028-046-0017	Nickel dithiocyanate	E, H	237-205-11	13689-92	Carc. Cat. 1; R49 Muta. Cat. 3; R68 Repr. Cat. 2; R61 T; R48/23 R42/43 R32 N; R50-53	T; N R: 49-61-32-42/43-48/23-68-50/53 S: 53-45-60-61 0,5 % ≤ C < 25 %: T, N; R49-61-42/43-48/23-68-51/53 1 % ≤ C < 2,5 %: T; R49-61-42/43-48/23-68-52/53 0,5 % ≤ C <		

**Status:** EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

							1 %: T; R49-61-43-48/20-52/53 0,25 % ≤ C < 0,5 %: T: R49-61-43-48/20-52/53 0,1 % ≤ C < 0,25 %: T; R49-43-48/20 0,01 % ≤ C < 0,1 %: Xi; R43
028-047-0012	nickel dichromate	E, H	239-646-5	15586-38	Carc. Cat. 1; R49 Muta. Cat. 3; R68 Repr. Cat. 2; R61 T; R48/23 R42/43 N; R50-53	T; N R: 49-61-42/43-48/23-68-50/53 S: 53-45-60-61	C ≥ 25 %: R49-61-42/43-48/23-68-50/53 0,5 % ≤ C < 25 %: T, N; R49-61-42/43-48/23-68-51/53 1 % ≤ C < 2,5 %: T; R49-61-42/43-48/23-68-52/53 0,5 % ≤ C < 1 %: T; 49-61-43-48/20-52/53 0,25 % ≤ C < 0,5 %: T; R49-43-48/20-52/53 0,1% ≤ C < 0,25 %: T; R49-43-48/20 0,01 % ≤ C 0,1 %: Xi; R43
028-048-0018	nickel(II) selenite	E, H	233-263-7	10101-96	Carc. Cat. 1; R49 T; R48/23 R42/43	T; N R: 49-42/43-48/23-50/53 S: 53-45-60-61	

*Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.*

					N; R50-53			
028-049-0013	nickel selenide	E, H	215-216-21314-05-2	21314-05-2	Carc. Cat. 1; R49 T; R48/23 R43 N; R50-53	T; N R: 49-43-48/23-50/53 S: 53-45-60-61		
028-050-0019	picric acid, lead nickel salt	E, H	—	68130-19	Carc. Cat. 1: R49 Repr. Cat. 1: R61 Repr. Cat. 3; R62 T; R48/23 R43 N; R50-53	T; N R: 49-61-43-48/23-62-50/53 S: 53-45-60-61		
028-051-0014	nickel diarsenide; [1] nickel arsenide [2]	E, H	235-103-1248-169-12016-75	12068-61 12016-75	Carc. Cat. 1; R49 T; R48/23 R43 N; R50-53	T; N R: 49-43-48/23-50/53 S: 53-45-60-61		
028-052-001X	nickel barium titanium primrose priderite; C.I. Pigment Yellow 157; C.I. 77900	E, H	271-853-668610-24	668610-24	Carc. Cat. 1: R49 T; R48/23 R43	T R: 49-43-48/23 S: 53-45		
028-053-0015	nickel dichlorate; [1] nickel dibromate; [2] ethyl hydrogen sulfate, nickel(II) salt [3]	E, H	267-897-061952-43 238-596-112550-87 275-897-713720-48	061952-43 112550-87 13720-48	Carc. Cat. 1; R49 T; R48/23 Cat. 3; R68 Repr. Cat. 2; R61 T; R48/23	T; N R: 49-61-42/43-48/23-68-50/53 S: 53-45-60-61 15 % ≤ C < 25 %: T, N: R49-61-42/43-48/23-68-51/53	C ≥ 25 %: R49-61-42/43-48/23-68-50/53 R49-61-42/43-48/23-68-50/53 15 % ≤ C < 25 %: T, N: R49-61-42/43-48/23-68-51/53	



*Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.*

				R42/43 N; R50-53		1 % ≤ C < 2,5 %: T: R49-61-42/43-48/23-68-52/53 0,5 % ≤ C < 1 %: T; R49-61-43-48/20-52/53 0,25 % ≤ C < 0,5 %: T; R49-43-48/20-52/53 0,1 % ≤ C < 0,25 %: T: R49-43-48/20 0,01 % ≤ C < 0,1 %: Xi; R43
028-054-00	nickel(II) E, H trifluoroacetate; [1] nickel(II) propionate; [2] nickel bis(benzenesulfonate); [3] nickel(II) hydrogen citrate; [4] citric acid, ammonium nickel salt; [5] citric acid, nickel salt; [6] nickel bis(2- ethylhexanoate); [7] 2- ethylhexanoic acid, nickel salt; [8] dimethylhexanoic acid nickel salt; [9]	240-235-8 [10] 222-102-6 [11] 254-642-3 [12] 242-533-3 [13] 242-161-1 [14] 245-119-0 [15] 224-699-9 [16] 231-480-1 [17] 301-323-2 [18] 249-555-2 [19] 248-585-3 [20] 284-349-6 [21] 300-094-6 [22] 287-468-1 [23] 287-469-7 [24] 257-447-1 [25] 300-093-0 [26] 276-205-6 [27] 258-051-1 [28] 237-138-8 [29] 287-470-2 [30] 287-471-8 [31] 284-347-5 [32] 284-351-7 [33] 285-698-7 [34] 285-909-2 [35] 284-348-0 [36] 287-592-6 [37] 294-302-1 [38] 283-972-0 [39]	16083-14-0 [1] 2349-08-4 [2] 19819-65-0 [3] 4721-51-0 [4] 8283-82-6 [5] 10605-92-1 [6] 4734-16-4 [7] 7880-31-6 [8] 9983-68-1 [9] 219017-63-4 [10] 37637-46-4 [11] 64832-37-9 [12] 650333-0 [13] 33408-43-6 [14] 33508-44-7 [15] 151818-56-5 [16] 393920-09-3 [17] 71937-07-8 [18] 152025-25-9 [19] 2634-40-5 [20] 82108-45-8 [21] 82208-46-9 [22] 82332-35-7 [23] 82432-39-1 [24] 82535-77-9 [25] 82666-19-4 [26] 82732-36-8 [27] 82831-28-6 [28] 92097-41-5 [29] 834076-45-4 [30]	Corr. Cat. R49 Mut. C [4] R [5] Rep. C [7] R [8] T [9] R [10] C [11] N [12] R [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30]	T; N R: 49-61-42/43-48/23-68-50/53 S: 53-45-60-015 %	C ≥ 25 %: 49-61-42/43-48/23-68-50/53 R49-61-42/43-48/23-68-50/53 0,5 % ≤ C < 25 %: T, N; R49-61-42/43-48/23-68-51/53 1 % ≤ C < 2,5 %: T; R49-61-42/43-48/23-68-52/53 0,5 % ≤ C < 1 %: T; R49-61-43-48/20-52/53 0,25 % ≤ C < 0,5 %: T; R49-43-48/20-52/53 0,1 % ≤ C < R49-43-48/20 0,01 % ≤ C <

---

**Status:** EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

---

nickel(II) isooctanoate; [10] nickel isooctanoate; [11] nickel bis(isononanoate); [12] nickel(II) neononanoate; [13] nickel(II) isodecanoate; [14] nickel(II) neodecanoate; [15] neodecanoic acid, nickel salt; [16] nickel(II) neoundecanoate; [17] bis(D- gluconato- $O^1, O^2$ )nickel; [18] nickel 3,5- bis( <i>tert</i> - butyl)-4- hydroxybenzoate (1:2); [19] nickel(II) palmitate; [20] (2- ethylhexanoato- <i>O</i> ) (isononanoato- <i>O</i> )nickel; [21] (isononanoato- <i>O</i> ) (isooctanoato- <i>O</i> )nickel; [22] (isooctanoato- <i>O</i> ) (neodecanoato- <i>O</i> )nickel; [23] (2- ethylhexanoato- <i>O</i> ) (isodecanoato- <i>O</i> )nickel; [24] (2- ethylhexanoato- <i>O</i> ) (neodecanoato- <i>O</i> )nickel; [25] (isodecanoato- <i>O</i> ) (isooctanoato- <i>O</i> )nickel; [26] (isodecanoato- <i>O</i> ) (isononanoato- <i>O</i> )nickel; [27] (isononanoato- <i>O</i> ) (neodecanoato- <i>O</i> )nickel; [28] fatty acids, C <sub>6-19</sub> - branched, nickel salts; [29]	- [31]	72319-19-8 [31]	0,1 %: Xi; R43
--	--------	-----------------	-------------------

*Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.*

	fatty acids, C <sub>8-18</sub> and C <sub>18</sub> -unsaturated, nickel salts; [30] 2,7-naphthalenedisulfonic acid, nickel(II) salt; [31]						
028-055-0016	nickel(II) sulfite; [1] nickel tellurium trioxide; [2] nickel tellurium tetraoxide; [3] molybdenum nickel hydroxide oxide phosphate [4]	E, H	231-827-7713 239-967-0128 239-974-9138 268-585-7681	2007-95-10 2007-52-21 2005-21-81 2013-36-48	Chf. Cat. R49 R3 R48/23 R42/43 N; R50-53	T; N R: 49-42/43-48/23-50/53 S: 53-45-60-61	
028-056-0010	nickel boride (NiB); [1] dinickel boride; [2] trinickel boride; [3] nickel boride; [4] dinickel silicide; [5] nickel disilicide; [6] dinickel phosphide; [7] nickel boron phosphide [8]	E, H	234-493-0120 234-494-6120 234-495-1120 235-723-2126 235-033-1120 235-379-3120 234-828-0120 - [8]	2007-00-01 2007-01-11 2007-02-21 2019-90-48 2009-14-45 2011-89-71 2013-64-50 65229-23-4	Chf. Cat. R49 R3 R48/23 R45 N[6] R50/53 R48	T; N R: 49-43-48/23-50/53 S: 53-45-60-61	
028-057-0017	nickel aluminium tetraoxide; [1] nickel titanium trioxide; [2]	E, H	234-454-8120 234-825-4120 235-752-0126 257-970-5125 268-169-5180 274-755-1106 238-034-5171 238-032-4181	2004-35-21 2013-39-11 2013-76-81 2012-12-48 2016-03-45 2009-92-93-2 2017-55-07 2017-51-68	Chf. Cat. R49 R3 R48/23 R45 R6 R7 R8	T R: 49-43-48/23 S: 53-45	

**Status:** EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

	nickel titanium oxide; [3] nickel divanadium hexaoxide; [4] cobalt dimolybdenum nickel octaoxide; [5] nickel zirkonium trioxide; [6] molybdenum nickel tetraoxide; [7] nickel tungsten tetraoxide; [8] olivine, nickel green; [9] lithium nickel dioxide; [10] molybdenum nickel oxide; [11]		271-112-7695 - [10] - [11]	60515-84-4 [9] 12031-65-1 [10] 12673-58-4 [11]			
028-058-002	cobalt lithium nickel oxide	E	442-750-5	—	Carc. Cat. 1; R49 T+; R26 T; R48/23 R43 N; R50-53	T+; N R: 49-26-43-48/23-50/53 S: 53-45-60-61	
029-014-005	mixture of: 2,2'- [[ <i>cis</i> -1,2- cyclohexanediylbis(nitrilomethylidene)]bis[phenolate]] (2-) <i>N,N</i> ' <i>O,O</i> '- copper complex; 2,2'- [[ <i>trans</i> -1,2- cyclohexanediylbis(nitrilomethyldiyne)]bis[phenolate]] (2-) <i>N,N</i> ' <i>O,O</i> '- copper complex		419-610-7171 866-243	43; R48/22 N; R50-53	Xn; N R: 48/22-51/53 S: (2-)22-36-61		

*Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.*

030-012-00	Aluminium-magnesium-zinc-carbonate-hydroxide	423-570-6	169314-88	R52-53	R: 52/53 S: 61		
030-015-00	Zinc(2+)bis(hexacyano)borate(3+)diacetate	440-060-9		R51-53	N R: 51/53 S: 61		
042-005-00	Mixture of: mono- and di-glycerols of canola oil; canola oil acid amide of branched 1,3-propanediamine, N-[3-(tridecyloxy)propyl]; N,N-diorgano dithiocarbamate molybdenum complex	434-240-6		R43 N; R51-53	Xi; N R: 43-51/53 S: (2-)24-37-61		
050-023-00	Mixture of: bis[(2-ethyl-1-oxohexyl)oxy]dioctyl stannane; bis[(2-ethyl-1-oxohexyl)oxy]dioctylstannyl]oxide; bis(1-phenyl-1,3-decanedionyl)dioctyl stannane; ((2-ethyl-1-oxohexyl)oxy)-(1-phenyl-1,3-decanedionyl)dioctyl stannane	422-920-5		Xn; R48/22 N; R50-53	Xn; N R: 48/22-50/53 S: (2-)23-36-05-06 0,01 ≤ C < 10 %: N; R50/53 0,25 % ≤ C < 2,5 %: N; R51/53 0,025 % ≤ C < 0,25 %: R52/53		

*Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.*

050-024-00	Mixture of: tri- <i>p</i> -tolyltin hydroxide; hexa- <i>p</i> -tolyl-distannoxane	432-230-6	—	T; R48/25 Xn; R22 Xi; R38-41 R43 N; R50-53	T; N R: 22-38-41-43-48/25-50/53 S: (1/2-)22-26-36/37/39-45-60-61		
064-001-00	Calcium(III)sulfite trihydrate	456-900-25	1285-81	N; R51-53	N R: 51/53 S: 61		
078-011-00	Hydrodisulfite platinum(II) acid	423-310-16	1420-92	Xn; R22-48/20 C; R35 R42/43 R52-53	C R21/22 22-35-42/43-48/20/21/22-52/53 S: (1/2-)23-24-26-28-36/37/39-45-61		
078-012-00	Platinum(IV) nitrate/nitric acid solution	432-400-1	—	C; R35 N; R50-53	C; N R: 35-50/53 S: (1/2-)26-36/37/39-45-60-61		
082-012-00	Barium calcium cesium lead samarium strontium bromide chloride fluoride iodide europium doped	431-780-41	199876-46	Xn; R22-48/22 N; R51-53	Xn; N R: 22-48/22-51/53 S: (2-)22-36-61		
601-080-00	Mixture of: <i>sec</i> -butylphenyl(phenyl)methane, mixed isomers; 1-( <i>sec</i> -butylphenyl(phenyl)-2-phenylethane, mixed isomers; 1-( <i>sec</i> -butylphenyl-1-phenylethane, mixed isomers	431-100-6	—	N; R50-53	N R: 50/53 S: 60-61		

*Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.*

601-081-00	cyclohexadeca-1,9-diene	431-730-1	4277-06-9	Xi; R38 R43 R53	Xi R: 38-43-53 S: (2-)36/37-61		
601-082-00	Mixture of: endo-2-methyl-exo-3-methyl-exo-2-[(exo-3-methylbicyclo[2.2.1]hept-exo-2-yl)methyl]bicyclo[2.2.1]heptane; exo-2-methyl-exo-3-methyl-endo-2-[(endo-3-methylbicyclo[2.2.1]hept-exo-2-yl)methyl]bicyclo[2.2.1]heptane	434-420-4	—	Xi; R38-41 N; R50-53	Xi; N R: 38-41-50/53 S: (2-)23-26-37/39-57-60-61		
601-083-00	endo-hexylbicyclo[2.2.1]hept-2-ene	435-000-3	22094-83	Xn; R65 Xi; R38 R53	Xn R: 38-65-53 S: (2-)37-62-61		
601-084-00	Mixture of: 5-endo-butylbicyclo[2.2.1]hept-2-ene; 5-exo-butylbicyclo[2.2.1]hept-2-ene (80:20)	435-180-3	—	Xn; R65 Xi; R38 N; R50-53	Xn; N R: 38-65-50/53 S: (2-)37-62-60-61		
602-105-00	Sodium 1,1,2,2,3,3,4,4,4-nonafluoro-1-butanefluorobutanesulfinate	422-100-7	102061-8	Xn; R41 R43	Xi R: 41-43 S: (2-)24-26-37/39		
602-106-00	2-bromo-4,6-difluoroaniline	429-430-0	444-14-4	Xn; R22 N; R51-53	Xn; N R: 22-51/53 S: (2-)25-61		

*Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.*

602-107-00	3,4,4-tetrafluoro-1-iodo-butene		439-500-233831-83	Xn; R22 Xi; R38 N; R51-53	Xn; N R: 22-38-51/53 S: (2-)37-61		
602-108-00	2,3,5,6-tetrafluorophenyl)methanol		443-840-74084-38-2	Xn; R22 Xi; R36 R43	Xn R: 22-36-43 S: (2-)26-36/37		
603-211-00	3-epoxypropyltrimethylammonium chloride ... %; glycidyl trimethylammonium chloride ... %	B E	221-221-03033-77-0	Carc. Cat. 2; R45 Muta. Cat. 3; R68 Repr. Cat. 3; R62 Xn; R21/22-48/22 Xi; R41 R43 R52-53	T R: 45-21/22-41-43-48/22-62-68-52/53 S: 53-45-61		
603-212-00	3,4,6,7,8-hexahydro-4,6,6,7,8,8-hexamethylindeno[5,6-c]pyran; galaxolide; (HHCB)		214-946-91222-05-5	N; R50-53	N R: 50/53 S: 60-61		
603-213-00	2-methoxy-2-methylbutane; tert-amyl methyl ether		213-611-4994-05-8	F; R11 Xn; R22 R67	F; Xn R: 11-22-67 S: (2-)9-16-23-33		
603-214-00	8-diisopropoxycyclohexane		413-740-81132-95-2	C; R34	C R: 34 S: (1/2-)23-26-36/37/39-45		
603-215-00	3-hydroxy-4-fluoro-1,4-diazoniabicyclo[2.2.2]octane bis(tetrafluoroborate)		418-330-2162241-33	E; R2 Xn; R22-48/22 Xi; R41 R43 N; R50-53	E; Xn; N R: 2-22-41-43-48/22-50/53 S: (2-)22-26-36/37/39-60-61		
603-216-00	9-1-amino-2,3-dihydro-1H-		422-660-27480-35-5	Xi; R41 R43 R52-53	Xi R: 41-43-52/53		



*Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.*

	inden-2-ol					S: (2-)24-26-37/39-61	
603-217-00-4,6-	tri- <i>tert</i> -butylphenyl 2-butyl-2-ethyl-1,3-propanediolphosphite		423-560-1161717-32R43	R53		Xi R: 43-53 S: (2-)24-37/39-61	
603-220-00-0	{benzyl[2-(2-methoxyphenoxy)ethyl]amino}-3-(9 <i>H</i> -carbazol-4-yl)oxypropan-2-ol		432-890-572955-94-R53	R53		R: 53 S: 61	
603-221-00-62-	amino-5-chlorophenyl)-2,2,2-trifluoro-1,1-ethanediol, hydrochloride; [containing < 0,1 % 4-chloroaniline (EC No 203-401-0)]		433-580-2214353-17Xn; R22	C; R34 N; R51-53		C; N R: 22-34-51/53 S: (1/2-)26-36/37/39-45-61	
603-221-01-82-	E amino-5-chlorophenyl)-2,2,2-trifluoro-1,1-ethanediol, hydrochloride; [containing ≥ 0,1 % 4-chloroaniline (EC No 203-401-0)]		433-580-2214353-17Carc. Cat.	2; R45 Xn; R22 C; R34 N; R51-53		T; N R: 45-22-34-51/53 S: 53-45-61	
603-222-00-2R,3S,4R,5R,7R,9R,10R,11S,13R,14S,15R,16S,17R,18S,19R,20S,21R,22S,23R,24S,25R,26S,27R,28S,29R,30S,31R,32S,33R,34S,35R,36S	[(4-dimethylamino-3-hydroxy-6-methyltetrahydropyran-2-yl)oxy]-2-ethyl-3,4,12-trihydroxy-9-methoxy-3,5,7,9,11,13-					Xi R: 36 S: (2-)26	

*Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.*

	hexamethyl-6,14-dioxo-1-oxacyclotetradecane					
603-223-00-7	cyclopentylidene cyclopentanol; 1,1'-bi(cyclopentyliden)-2-ol	434-270-1	16261-30-9	Xi; R38-41 R52-53	Xi R: 38-41-52/53 S: (2-)26-37/39-61	
603-224-00-2	ethoxy-1,1,1,2,3,4,4,5,5,6,6,6-dodecafluoro-2-(trifluoromethyl)-hexane	435-790-1	1297730-9	R53	R: 53 S: 61	
603-225-00-8	Frithromycin A9-oxime (E); (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-4-((2,6-didesoxy-3-C-methyl-3-O-methyl- $\alpha$ -L-ribohexopiranosyl)oxy)-14-ethyl-7,12,13-trihydroxy-3,5,7,9,11,13-hexamethyl-6-((3,4,6-tridesoxy-3-dimethylamino- $\beta$ -D-xylohexapiranosyl)oxy)oxacyclotetradecan-2-ona-10-oxime (E)	437-070-0	13127-18-9	N; R51-53	N R: 51/53 S: 61	
603-226-00-3	(4-(4-methoxyphenyl)-1,3,5-triazin-2,4-diyl)bisbenzene-1,3-diol	444-500-0	1440-00-2	R52-53	R: 52/53 S: 61	
603-227-00-9	Hydro- $\omega$ -[[[(1,1-dimethylethyl)dioxy]carbonyl]oxy]-poly[oxy(methyl-1,2-ethanediyl)] ether	445-060-2	2203574-0	CB, R7 N; R50-53	O; N R: 7-50/53 S: (2-)3/7-14-36/37/39-60-61	

*Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.*

	with 2,2- bis(hydroxymethyl)-1,3- propanediol (4:1); reaction product of: $\alpha$ - hydro- $\omega$ - ((chlorocarbonyl)oxy)- poly(oxy(methyl-1,2- ethanediyl)) ether with 2,2- bis(hydroxymethyl)-1,3- propanediol with potassium 1,1- dimethylethylperoxalate						
603-228-00-04	( <i>R*,R*</i> )-6- fluoro-3,4- dihydro-2- oxiranyl-2 <i>H</i> -1- benzopyran; 6- fluoro-2- (2- oxiranyl)chromane	419-620-1	—	R43 N; R51-53	Xi; N R: 43-51/53 S: (2-)36/37-61		
603-229-00-X	sodium ( <i>Z</i> )-3- chloro-3- (4- chlorophenyl)-1- hydroxy-2- propene-1- sulfonate	420-800-7	—	Xi; R38-41 R43 N; R50-53	Xi; N R: 38-41-43-50/53 S: (2-)24-26-37/39-60-61		
603-230-00-00	5,6,6,7,8,8- hexamethyldecahydro-2 <i>H</i> - indeno[4,5- b]furan	440-030-5	—	Xi; R38-41 R53	Xi R: 38-41-53 S: (2-)26-37/39-61		
603-231-00-00	( <i>S</i> )-1,1- diphenyl-1,2- propanediol	443-220-6	—	R52-53	R: 52/53 S: 22-61		
603-232-00-00	3,3,8,8,10,10- hexamethyl-9-	444-420-6	—	R53	R: 53 S: 61		

*Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.*

	[1-(4-oxiranylmethoxyphenyl)ethoxy]-1,5-dioxo-9-aza-spiro[5.5]undecane					
603-233-00	Mixture of: 4-(1,3a,4,6,7,7a-hexahydro-4,7-methanoinden-5-ylidene)-3-methylbutan-2-ol; 4-(3,3a,4,6,7,7a-hexahydro-4,7-methanoinden-5-ylidene)-3-methylbutan-2-ol; 1-(1,3a,4,6,7,7a-hexahydro-4,7-methanoinden-5-ylidene)pentan-3-ol; 1-(3,3a,4,6,7,7a-hexahydro-4,7-methanoinden-5-ylidene)pentan-3-ol; (E)-4-(3a,4,5,6,7,7a-hexahydro-1H-4,7-methanoinden-5-yl)-3-methylbut-3-en-2-ol; (E)-4-(3a,4,5,6,7,7a-hexahydro-3H-4,7-methanoinden-5-yl)-3-methylbut-3-en-2-ol	444-430-0		N; R51-53	N R: 51/53 S: 61	
603-234-00	(1R,4R)-4-methoxy-2,2,7,7-tetramethyltricyclo(6.2.1.0(1,6))undec-5-ene	444-480-3		Xi; R38 N; R51-53	Xi; N R: 38-51/53	

**Status:** EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

					S: (2-)37-61		
604-074-00-6	tetrabromobisphenol A; 2,2',6,6'- tetrabromo-4,4'- isopropylidenediphenol	201-236-979-94-7		N; R50-53	N R: 50/53 S: 60-61		
604-075-00-6	(1,1,3,3- tetramethylbutyl)phenol; 4- <i>tert</i> - octylphenol	205-426-2140-66-9		Xi; R38-41 N; R50-53	Xi; N R: 38-41-50/53 S: (2-)26-37/39-60-61	C ≥ 20 %: Xi, N; R38-41-50/53 5 % ≤ C < 10 %: Xi, N; R41-50/53 R36-50/53 2,5 % ≤ C < 5 %: N; R50/53 0,25 % ≤ C < 2,5 %: N; R51/53 0,025 % ≤ C < 0,25 %: R52/53	
604-076-00-1	phenolphthalein	201-004-777-09-8		Carc. Cat. 2; R45 Muta. Cat. 3; R68 Repr. Cat. 3; R62	T R: 45-62-68 S: 53-45	C ≥ 5 %: T; R45-62-68 1 % ≤ C < 5 %: T; R45-68	
604-077-00-7	benzotriazol-2- yl-4- methyl-6- (2- methylallyl)phenol	419-750-998809-58		R53	R: 53 S: 61		
604-079-00-8	(1,3- phenylene-	428-970-413595-25		Repr.Cat.3 R62 R43	Xn; N R: 43-62-51/53		

*Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.*

	bis(1-methylethylidene))bis-phenol				N; R51-53	S: (2-)22-36/37-61		
604-080-00-3	fluoro-3-trifluoromethylphenol		432-560-061721-07		Xn; R20 C; R35 R43 N; R51-53	C; N R: 20-35-43-51/53 S: (1/2-)26-28-36/37/39-45-61		
604-081-00-9	bis(4-hydroxyphenyl)-1-phenylethane		433-130-51571-75-1		N; R50-53	N R: 50/53 S: 25-60-61		
604-082-00-4	chloro-6-fluoro-phenol	E	433-890-82040-90-6		Muta.Cat.2F; R46 Repr.Cat.3 R62 Xn; R22 C; R34 R43 N; R51-53	F; N R: 346-22-34-43-62-51/53 S: 53-45-61		
604-083-00-4'-X	sulfonylbisphenol, polymer with ammonium chloride(NH <sub>4</sub> Cl), pentachlorophosphorane and phenol		439-270-3260408-02		R53	R: 53 S: 61		
604-084-00-5	ethoxy-2,3-difluorobenzene		441-000-4121219-07		Xn; R22 R52-53	Xn R: 22-52/53 S: (2-)23-61		
604-087-00-1	mixture of: 1,2-naphthoquinonediazide-5-sulfonylchloride (or sulfonic acid)monoester with 4,4'-(1-(4-(1-(4-hydroxyphenyl)-1-methylethyl)phenyl)ethylidene)bisphenol; 1,2-naphthoquinonediazide-5-		433-640-8—		F; R17 R44 R53	F R: 17-44-53 S: (2-)15-22-61		

**Status:** EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

	sulfonylchloride (or sulfonic acid)diester with 4,4'-(1- (4-(1-(4- hydroxyphenyl)-1- methylethyl)phenyl)ethylidene)bisphenol; 1,2- naphthoquinonediazide-5- sulfonylchloride (or sulfonic acid)triester with 4,4'-(1- (4-(1-(4- hydroxyphenyl)-1- methylethyl)phenyl)ethylidene)bisphenol						
604-089-00-2	methyl-5- <i>tert</i> -butylthiophenol	444-970-7	—	R10 Repr.Cat.3 R63 Xn; R48/20/22(85) Xi; R36/38 R43 R67 N; R50-53	Xn; N R: 10-36/38-43-48/20/22-63-65-67-50/53 S: (2-26-36/37-62-60-61		
605-037-00-1	<i>trans</i> -3-[2-(7-chloro-2-quinolinyl)vinyl]benzaldehyde; 3-[( <i>E</i> )-2-(7-chloro-2-quinolinyl)vinyl]benzaldehyde	421-800-1	120578-0	R23	R: 53 S: 22-61		
605-038-00-7	methyl-5-phenylpentan-1-al	433-900-0	55066-49	Xn; R22 Xi; R38 R43 N; R51-53	Xn; N R: 22-38-43-51/53 S: (2-)36/37-61		
605-039-00-2	2-dihydroxy-5-nitrobenzaldehyde	441-810-8	116313-8	Xn; R22 Xi; R41 R43	Xn R: 22-41-43 S: (2-)22-24-26-37/39		

*Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.*

606-124-00-7			421-080-7161462-35	Xn; R48/22 N; R50-53	Xn; N R: 48/22-50/53 S: (2-)36-60-61		
	cyclopropyl-3-(2-methylthio-4-trifluoromethylphenyl)-1,3-propanedione						
606-125-00-2			421-340-16777-05-5	Xn; R22	Xn R: 22 S: (2-)22		
	benzylimidazolidine-2,4-dione						
606-126-00-8			421-470-799788-75	N; R51-53	N R: 51/53 S: 61		
	bis(2,3-dihydroxypropylamino)anthraquinone						
606-128-00-9'			422-650-8148935-94	R53	R: 53 S: 61		
	(1,3-phenylene)bis[5-chloro-1 <i>H</i> -isoindole]-1,3(2 <i>H</i> )-dione						
606-129-00-4			423-090-7156732-13	R53	R: 53 S: 61		
	amino-[2 <i>S</i> -di(methylphenylamino)-1,6-diphenyl-4 <i>Z</i> -hexen-3-one; (2 <i>S</i> ,4 <i>Z</i> )-5-amino-2-(dibenzylamino)-1,6-diphenylhex-4-en-3-one						
606-130-00-X			423-860-256309-94	R43 R52-53	Xi R: 43-52/53 S: (2-)24-37-61		
	(1,4-dioxaspiro[4.5]dec-8-yl)-cyclohexanone						
606-131-00-5	E		427-230-85571-36-8	Repr. Cat. 2; R60 Xn; R48/22 N; R51-53	T; N R: 60-48/22-51/53 S: 53-45-61		
	cyclic 3-(1,2-ethanediyloacetale)-estra-5(10),9(11)-diene-3,17-dione						
606-132-00-6			433-490-36563-83-3	R43 R52-53	Xi R: 43-52/53 S: (2-)24-37-61		
	(6 <i>S</i> )-6,19-epoxyandrost-4-ene-3,17-dione						



*Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.*

606-134-00	Androsta-1,4,9(11)-triene-3,17-dione	433-560-3	15375-21	Repr. Cat.3; R62	Xn R: 62 S: (2-)22-36/37		
606-135-00	Cyclohexadecanone	438-930-8	25550-52-9	R53	R: 53 S: 61		
606-136-00	3,6R,9S,12R,15S,18R,21S,24R,27S,30S,33R,36R,39S,42R,45S,48R,51S,54R,57S,60S,63R,66S,69R,72S,75R,78S,81R,84S,87R,90S,93R,96S,99R,102S,105R,108S,111R,114S,117R,120S,123R,126S,129R,132S,135R,138S,141R,144S,147R,150S,153R,156S,159R,162S,165R,168S,171R,174S,177R,180S,183R,186S,189R,192S,195R,198S,201R,204S,207R,210S,213R,216S,219R,222S,225R,228S,231R,234S,237R,240S,243R,246S,249R,252S,255R,258S,261R,264S,267R,270S,273R,276S,279R,282S,285R,288S,291R,294S,297R,300S,303R,306S,309R,312S,315R,318S,321R,324S,327R,330S,333R,336S,339R,342S,345R,348S,351R,354S,357R,360S,363R,366S,369R,372S,375R,378S,381R,384S,387R,390S,393R,396S,399R,402S,405R,408S,411R,414S,417R,420S,423R,426S,429R,432S,435R,438S,441R,444S,447R,450S,453R,456S,459R,462S,465R,468S,471R,474S,477R,480S,483R,486S,489R,492S,495R,498S,501R,504S,507R,510S,513R,516S,519R,522S,525R,528S,531R,534S,537R,540S,543R,546S,549R,552S,555R,558S,561R,564S,567R,570S,573R,576S,579R,582S,585R,588S,591R,594S,597R,600S,603R,606S,609R,612S,615R,618S,621R,624S,627R,630S,633R,636S,639R,642S,645R,648S,651R,654S,657R,660S,663R,666S,669R,672S,675R,678S,681R,684S,687R,690S,693R,696S,699R,702S,705R,708S,711R,714S,717R,720S,723R,726S,729R,732S,735R,738S,741R,744S,747R,750S,753R,756S,759R,762S,765R,768S,771R,774S,777R,780S,783R,786S,789R,792S,795R,798S,801R,804S,807R,810S,813R,816S,819R,822S,825R,828S,831R,834S,837R,840S,843R,846S,849R,852S,855R,858S,861R,864S,867R,870S,873R,876S,879R,882S,885R,888S,891R,894S,897R,899S,901R,903S,905R,907S,909R,911S,913R,915S,917R,919S,921R,923S,925R,927S,929R,931S,933R,935S,937R,939S,941R,943S,945R,947S,949R,951S,953R,955S,957R,959S,961R,963S,965R,967S,969R,971S,973R,975S,977R,979S,981R,983S,985R,987S,989R,991S,993R,995S,997R,999S	442-150-6	1135418-70	X4; R36 R53	Xi R: 36-53 S: (2-)26-61		
606-137-00	8ns-7,7'-dimethyl-(4H,4H)- $\lambda$ -(2,2')bi[benzo[1,4]thiazinylidene]-3,3'-dione	444-750-0	211387-26	R53	R: 53 S: 22-61		
606-138-00	23-butyl-5-nitrobenzofuran-3-yl)[4-(3-dibutylaminopropoxy)phenyl]methanone	444-800-1	141645-23	R10 Xn; R22-48/221 Xi; R38-41 R43 N; R50-53	Xn; N R: 210-22-38-41-43-48/22-50/53 S: (2-)23-26-30/37/39-60-61	C $\geq$ 25 %: N41N48/22-50/53 R22-38-41-43-48/22-50/53 10 % $\leq$ C < 25 %: Xn, N; R38-41-43-48/22-50/53 20 %: Xn, N; R41-43-48/22-50/53 5 % $\leq$ C < 10 %: Xi, N; R36-43-50/53 2,5 % $\leq$ C < 5 %: Xi, N; R43-50/53 1 % $\leq$ C < 2,5 %: Xi, N; R43-51/53 0,25 % $\leq$ C < 1 %: N; R51/53	

*Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.*

						0,025 % ≤ C < 0,25 %: R52/53	
606-139-00	X	444-830-5124379-29R53	(3,4-dichlorophenyl)-3,4-dihydro-2H-naphthalen-1-one			R: 53 S: 61	
606-140-00	X	444-860-9474510-57Xn;	4-hydroxy-1-(4-(4-(2-hydroxy-2-methylpropionyl)benzyl)phenyl)-2-methylpropan-1-one			R48/22 N; R50-53	Xn; N R: 48/22-50/53 S: (2-)22-36-60-61
606-141-00	X	418-410-7—	Sodium 3-(methoxycarbonyl)-4-oxo-3,4,5,6-tetrahydro-2-pyridinolate			Xi; R36	Xi R: 36 S: (2-)26
606-142-00	X	434-290-9—	Mixture of: (1R,2SR,7SR,8SR,E) 9 and 10-ethylidene-3-oxatricyclo[6.2.1.0 <sup>(2,7)</sup> ]undecan-4-one; (1R,2SR,7SR,8SR,Z)-10-ethylidene-3-oxatricyclo[6.2.1.0 <sup>(2,7)</sup> ]undecan-4-one; (1R,2SR,7SR,8SR,Z)-9-ethylidene-3-oxatricyclo[6.2.1.0 <sup>(2,7)</sup> ]undecan-4-one			Xn; R22 N; R51-53	Xn; N R: 22-51/53 S: (2-)61
607-580-00	X	422-360-1100491-29R43	ethyl 7-chloro-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylate			R43 N; R51-53	Xi; N R: 43-51/53 S: (2-)22-24-37-61

*Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.*

607-618-00	06 sodium bisulfite; 2- naphthalenesulfonic acid,1,2,3,4- tetrahydro-2- methyl-1,4- dioxo-, sodium salt	204-987-0	130-37-0	Xi; R36/38 N; R50-53	Xi; N R: 36/38-50/53 S: (2-)24/25-60-61		
607-619-00	06 nicotinamide bisulfite; 1,2,3,4- tetrahydro-2- methyl-1,4- dioxonaphthalene-2- sulfonic acid, compound with nicotin-3- amide (1:1)	277-543-7	73581-79-0	Xi; R36/38 N; R50-53	Xi; N R: 36/38-50/53 S: (2-)24/25-60-61		
607-620-00	06 sodium nitritotriacetate	225-768-6	5064-31-3	Carc. Cat. 3; R40 Xn; R22 Xi; R36	Xn R: 22-36-40 S: (2-)26-36/20-40	C ≥ 25 %: Xn; R22-36-40 C < 25 %: Xn; R36-40 5 ≤ % C < 20 %: Xn; R40	
607-621-00	06 milbemectin (ISO); [mixture of milbemycin A3 (CAS No 51596-10-2) and milbemycin A4 (CAS No	—	—	Xn; R20/22 N; R50-53	Xn; N R: 20/22-50/53 S: (2-)46-60-01	C ≥ 25 %: Xn, N; R20/22-50/53 0,25 % ≤ C < 25 %: N; R50/53 0,025 % ≤ C < 0,25 %: N; R51/53	

*Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.*

	51596-11-3) (30:70)]						0,0025 % ≤ C < 0,025 %: R52/53
607-622-00-7	ethylhexyl-2-ethylhexanoate	231-057-17425-14-1		Repr. Cat. 3; R63	Xn R: 63 S: (2-)36/37		
607-623-00-2	diisobutyl phthalate	201-553-284-69-5		Repr. Cat. 2; R61 Repr. Cat. 3; R62	T R: 61-62 S: 53-45	C ≥ 25 %: T; R61-62 5 % ≤ C < 25 %: Xn; R62	
607-624-00-8	perfluorooctane sulfonic acid; heptadecafluorooctane sulfonic acid; [1] potassium perfluorooctanesulfonate; potassium heptadecafluorooctane-1-sulfonate; [2] diethanolamine perfluorooctane sulfonate; [3] ammonium perfluorooctane sulfonate; ammonium heptadecafluorooctanesulfonate; [4] lithium perfluorooctane sulfonate; lithium heptadecafluorooctanesulfonate [5]	217-179-81763-23-1 220-527-12295-39-3 274-460-87025-14-8 249-415-029081-56-0 249-644-629457-72-6	1763-23-1 12295-39-3 87025-14-8 29081-56-0 29457-72-6	Chc. Cat. 2; R40 Chc. Cat. 2; R41 Chc. Cat. 2; R42 Chc. Cat. 2; R43 Chc. Cat. 2; R44 Chc. Cat. 2; R45 Chc. Cat. 2; R46 Chc. Cat. 2; R47 Chc. Cat. 2; R48 Chc. Cat. 2; R49 Chc. Cat. 2; R50 Chc. Cat. 2; R51 Chc. Cat. 2; R52 Chc. Cat. 2; R53 Chc. Cat. 2; R54 Chc. Cat. 2; R55 Chc. Cat. 2; R56 Chc. Cat. 2; R57 Chc. Cat. 2; R58 Chc. Cat. 2; R59 Chc. Cat. 2; R60 Chc. Cat. 2; R61 Chc. Cat. 2; R62 Chc. Cat. 2; R63 Chc. Cat. 2; R64 Chc. Cat. 2; R65 Chc. Cat. 2; R66 Chc. Cat. 2; R67 Chc. Cat. 2; R68 Chc. Cat. 2; R69 Chc. Cat. 2; R70 Chc. Cat. 2; R71 Chc. Cat. 2; R72 Chc. Cat. 2; R73 Chc. Cat. 2; R74 Chc. Cat. 2; R75 Chc. Cat. 2; R76 Chc. Cat. 2; R77 Chc. Cat. 2; R78 Chc. Cat. 2; R79 Chc. Cat. 2; R80 Chc. Cat. 2; R81 Chc. Cat. 2; R82 Chc. Cat. 2; R83 Chc. Cat. 2; R84 Chc. Cat. 2; R85 Chc. Cat. 2; R86 Chc. Cat. 2; R87 Chc. Cat. 2; R88 Chc. Cat. 2; R89 Chc. Cat. 2; R90 Chc. Cat. 2; R91 Chc. Cat. 2; R92 Chc. Cat. 2; R93 Chc. Cat. 2; R94 Chc. Cat. 2; R95 Chc. Cat. 2; R96 Chc. Cat. 2; R97 Chc. Cat. 2; R98 Chc. Cat. 2; R99 Chc. Cat. 2; R100	T; N R: 61-20/22-40-48/25-64-51/53 S: 53-45-61		
607-625-00-3	dinafopropargyl (ISO)	—	105512-06	Xn; R22-48/22 R43 N; R50-53.	Xn; N R: 22-43-48/22-50/53 S: (2-)24-36/30-46-60-61	C ≥ 25 %: Xn; R53 R22-43-48/22-50/53 ≤ C < 25 %: Xn, N; R43-48/22-51/53 2,5 % ≤ C < 10 %:	

*Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.*

							Xi, N; R43-51/53 0,25 % ≤ C < 2,5 %: Xi; R43-52/53 0,001 % ≤ C < 0,25 %: Xi; R43
607-626-00	ethyl 1-(2,4- dichlorophenyl)-5- (trichloromethyl)-1H-1,2,4- triazole-3- carboxylate		401-290-5	103112-3	50	Carc. Cat. 2 R45 N; R50-53	Xn; R20 R: 45-50/53 S: 53-45-60-61
607-627-00	(4S,5S)-4- benzyl-2- oxo-5- oxazolidinyl]methyl 4- nitrobenzenesulfonate		416-360-0	162221-2	83	R43	Xi R: 43 S: (2-)22-24-37
607-628-00 X	oxo-4- (p- tolyl)butyric acid adduct with 4- ethylmorpholine		419-240-6	171054-8	91	Xn; R41	Xi R: 41 S: (2-)26-39
607-629-00	[2- methyl-1- (1- oxopropoxy)propoxy] (4- phenylbutyl)phosphinyl] acetic acid		419-270-1	123599-8	26	Xn; R36	Xi R: 36 S: (2-)26
607-630-00	acrylic acid, 3- (trimethoxysilyl)propyl ester		419-560-6	4369-14-6	6	Xn; R20 C; R34 R43 R52-53	C R: 20-34-43-52/53 S: (1/2-)26-36/37/39-45-61
607-631-00	mixture of: 2-(2- ((oxo(phenyl)acetyl)oxy)ethoxy)ethyl oxo(phenyl)acetate;		442-300-8	—	—	R43	Xi R: 43 S: (2-)24-37

*Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.*

	(2-(2-hydroxyethoxy)ethyl)oxo(phenyl)acetate						
607-632-00-1	3-(2,4-di-(1,1-dimethylpropyl)phenoxy)-propyl]-1-hydroxy-5-(2-methylpropyl-oxycarbonylamino)-naphthamide	420-210-1111244-14	4853		R: 53 S: 61		
607-633-00-7	Sodium 5- {[4-chloro-6-(1-naphthylamino)-1,3,5-triazin-2-yl]amino}-4-hydroxy-3-[(E)-(4-methoxy-2-sulfonatophenyl)diazenyl]-2,7-naphthalenedisulfonate	440-480-2341026-59	93; R41 R43		Xi R: 41-43 S: (2-)22-24-26-37/39		
607-634-00-5	(-)-2-acetoxypropionylchloride; (1S)-2-chloro-1-methyl-2-oxoethyl acetate	420-610-436394-75	Xn; R22 C; R34 R43		C R: 22-34-43 S: (1/2-)23-26-36/37/39-45		
607-635-00-8	Sodium N-(3-propionato)-L-aspartate	422-090-4172737-80	Xi; R41		Xi R: 41 S: (2-)26-39		
607-636-00-3	bromo-2-methylpropyl propionate	422-900-6158894-67	R10 Carc.Cat.3 R40 C; R34 R43		C R: 10-34-40-43 S: (1/2-)7/9-8-23-26-36/37/39-45		
607-637-00-9	Sodium 8-amino-5-{4-[2-	423-730-5250688-43	Xn; R41		Xi R: 41 S: (2-)26-39		

*Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.*

	(sulfonatoethoxy)sulfonyl]phenylazo}naphthalene-2-sulfonate					
607-638-00-4	hydroxybenzoic acid 2-butyl octyl ester	431-090-3190085-4	1R53	R: 53 S: 61		
607-639-00-X	(2-oxo-5-(1,1,3,3-tetramethylbutyl)-2,3-dihydro-1-benzofuran-3-yl)-4-(1,1,3,3-tetramethylbutyl)phenyl acetate	431-770-1216698-0	7R63	R: 53 S: 61		
607-641-00-0	(formylamino)-3-thiophenecarboxylic acid; 2-formamido-3-thiophenecarboxylic acid	431-930-943028-69	Xn; R22 R43	Xn R: 22-43 S: (2-)22-24-37		
607-642-00-6,9-	trithiaundecamethylene-1,11-dimethacrylate	432-210-7141631-22	2N R50-53	N R: 50/53 S: 60-61		
607-643-00-0	dimethyl (2S)-2-hydroxysuccinate	432-310-0617-55-0	R10 Xi; R41 R43	Xi R: 10-41-43 S: (2-)24-26-37/39-43		
607-644-00-0	dimethyl 2,2-dimethyl-6-methylenecyclohexanecarboxylate	432-350-981752-87	Xi; R38	Xi R: 38 S: (2-)37		
607-645-00-0	potassium 2-(4-fluoro-6-(methyl-(2-(sulfatoethylsulfonyl)ethyl)amino)-1,3,5-triazin-2-ylamino)-5-hydroxy-6-(4-methyl-2-	432-550-6243858-0	Xi; R41	Xi R: 41 S: (2-)22-26-39		

*Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.*

	sulfonatophenylazo)naphthalene-1,7-disulfonate					
607-646-00-8	erythro-hexanoic acid 2,4-dideoxy-3,5-O-(1-methylethylidene)-1,1-dimethylethylester; <i>tert</i> -butyl 2-[(4 <i>R</i> ,6 <i>S</i> )-6-(hydroxymethyl)-2,2-dimethyl-1,3-dioxan-4-yl]acetate	432-960-5124655-09	Xn; R22	Xn R: 22 S: (2-)25		
607-647-06-3	acetoxy-2-( <i>R,S</i> )butyryloxymethyl-1,3-oxathiolane	433-530-1143446-73	Xn; R22 R43 N; R50	Xn; N R: 22-43-50 S: (2-)24-37-57-61		
607-649-00-34	(chlorocarbonyl)-2-methylphenyl]acetate	433-690-0167678-46	R35 R43	C R: 35-43 S: (1/2-)7/8-26-36/37/39-45		
607-650-00-X	methyl-1,5-pentanediamine-1,3-benzenedicarboxylate	433-910-5145153-52	R23	Xi R: 43 S: (2-)24-37		
607-651-06-5	2-(nonanoyloxy)benzenesulfonate	434-360-991125-43	Xi; R41 R43	Xi R: 41-43 S: (2-)24-26-37/39		
607-652-00-0	ethyl <i>N</i> <sup>2</sup> -dodecanoyl-L-argininate hydrochloride	434-630-660372-77	Xi; R41 N; R50	Xi; N R: 41-50 S: (2-)26-39-61		
607-653-00-6	trakis(bis(2-hydroxyethyl)methylammonium) 3-(4-(7-acetylamino-1-hydroxy-3-sulfonatophthalen-2-ylazo)-5-methoxy-2-sulfonatophenylazo)-7-(4-	434-840-8225786-91	N R51-53	N R: 51/53 S: 61		



**Status:** EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

	amino-3-sulfonatophenylamino)-4-hydroxynaphthalene-2-sulfonate						
607-654-0051	5-3-hydroxy- $\gamma$ -butyrolactone	434-990-47331-52-4		R43	Xi R: 43 S: (2-)23-24-37		
607-655-0071	ethyl 6,8-dichlorooctanoate	435-080-11070-64-0		R43 N; R51-53	Xi; N R: 43-51/53 S: (2-)24-37-61		
607-656-0021	potassium salt of 4-amino-3,6-bis[[5-[[4-chloro-6-[(2-methyl-4-sulfophenyl)amino]-1,3,5-triazin-2-yl]amino]-2-sulfophenyl]azo]-5-hydroxy-2,7-naphthalenedisulfonic acid	435-350-7141250-43		Xi; R41 R52-53	Xi R: 41-52/53 S: (2-)22-26-39-61		
607-657-0028	potassium 7-(4-(4-(3-(2-sulfatoethanesulfonyl)phenylamino)-6-(4-(2-sulfatoethanesulfonyl)phenylamino)-1,3,5-triazin-2-ylamino)-2-ureidophenylazo)naphthalene-1,3,6-trisulfonate	436-920-8172399-10		Xi; R41	Xi R: 41 S: (2-)22-26-39		
607-658-0030	10-diamino-6,13-dichloro-2-(((6-(((4-(1,1-dimethylethyl)phenyl)sulfonyl)amino)-2-naphthalenyl)sulfonyl)-4,11-triphenodioxazinedisulfonic acid, lithium potassium	440-770-9371921-63		Xi; R41 R52-53	Xi R: 41-52/53 S: (2-)26-39-61		

*Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.*

	sodium salt						
607-659-00	009 Pentasodium N-[5-[[4-[[3-[(aminocarbonyl)amino]-4-[(3,6,8-trisulfonatonaphthalen-2-yl)azo]phenyl]amino]-6-chloro-1,3,5-triazin-2-yl]amino]-2-sulfonato-4-[[4-[-2-(oxysulfonato)ethyl]sulfonyl]phenyl]azo]phenyl]-3-aminopropanoic acid	442-030-0321912-47	442-030-0321912-47	Xi, R41	Xi R: 41 S: (2-)22-26-39		
607-660-00	0044- [4-[4-fluoro-6-(2-(2-vinylsulfonylethoxy)ethylamino)-1,3,5-triazin-2-ylamino]phenylazo]phenylazo} naphthalene-4,6,8-trisulfonate, trisodium salt	442-230-8321679-52	442-230-8321679-52	Xi, R41	Xi R: 41 S: (2-)22-26-39		
607-661-00	001- dimethylethyl 4'- (bromomethyl)biphenyl-2-carboxylate	442-850-9114772-40	442-850-9114772-40	R43 R53	Xi R: 43-53 S: (2-)22-24-37-61		
607-662-00	005 ethyl 2- (acetylamino)-3-chloropropionate	442-860-387333-22	442-860-387333-22	R43 N; R50-53	Xi; N R: 43-50/53 S: (2-)24-37-60-61		
607-663-00	006 (2-ethylhexyl) naphthalene-2,6-dicarboxylate	442-980-6127474-91	442-980-6127474-91	R53	R: 53 S: 61		
607-664-00	006 ethyl 2- chlorosulfonyl-4- (methanesulfonylaminoethyl) benzoate	443-120-2393509-79	443-120-2393509-79	Xi, R41 N; R51-53	Xi; N R: 41-51/53 S: (2-)26-39-61		
607-665-00	004 ns- methyl-2-	443-150-6101226-85	443-150-6101226-85	R10	R: 10 S: 23		

*Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.*

	ethyl- but-2- enoate						
607-666-0025	(benzyloxy)-2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-5-oxopentanoic acid	443-560-588784-33			Xi; R36	Xi R: 36 S: (2-)26	
607-667-0011	chloro-1-ethylcyclohexyl carbonate	444-950-899464-83			Muta.Cat. R68 R43	Xn R: 43-68 S: (2-)23-36/37	
607-668-0048	isopropyl-5-carboxy-1,3-dioxane	445-770-242031-28			Xi; R41 R52-53	Xi R: 41-52/53 S: (2-)22-26-39-61	
607-669-0013	methyl (9-acetoxy-3,8,10-triethyl-7,8,10-trimethyl-1,5-dioxo-9-aza-spiro[5.5]undec-3-yl)octadecanoate	445-990-9376588-17			R43 R53	Xi R: 43-53 S: (2-)24-37-61	
607-670-0010	dibutyl-3-(4-(5-ammonio-2-butyl)benzofuran-3-yl)carbonyl)phenoxy)propyl ammonium oxalate; (5-amino-2-butylbenzofuran-3-yl) [4-(3-dibutylaminopropoxy)phenyl]methanone, dioxalate	448-700-9500791-70			Xn; R48/22 Xi; R41 R43 N; R50-53	Xn; N R: 41-43-48/22-50/53 S: (2-)22-26-30/37/39-60-61 < 10 %: Xi, N; R36-43-50/53 2,5 % ≤ C < 5 %: Xi, N; R43-50/53 1 % ≤ C < 2,5 %: Xi, N; R43-51/53 0,25 % ≤ C < 1 %: N; R51/53	

**Status:** EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

						0,025 % ≤ C < 0,25 %: R52/53	
607-671-00	Diethyl 1,4- cyclohexanedicarboxylate	417-310-07	2903-27	Xn; R51-53	N R: 51/53 S: 61		
607-672-00 X	Mixture of: 2- hydroxy-3- (methacryloyloxy)propyl (2- benzoyl)benzoate; 1- hydroxymethyl-2- (methacryloyloxy)ethyl (2- benzoyl)benzoate; x- hydroxy- y- (methacryloyloxy)propyl(or -ethyl) (2- benzoyl)benzoate	419-000-0	—	R43 N; R51-53	Xi; N R: 43-51/53 S: (2-)24-37-61		
607-673-00	5- ethyl-5,6,7,8- tetrahydroquinolinium tosylate	419-570-0	—	Xn; R22 R52-53	Xn R: 22-52/53 S: (2-)61		
607-674-00	Branched C <sub>10</sub> - alkyl benzoates	421-090-11	131298-44	Xn; R20	Xn R: 20 S: (2-)23		
607-675-00	Mixture of: <i>cis</i> -9- octadecenedioic acid; <i>cis</i> -9- <i>cis</i> -12- octadecadienedioic acid; hexadecanedioic acid; octadecanedioic acid	422-260-8	—	Xi; R41 N; R50-53	Xi; N R: 41-50/53 S: (2-)26-39-60-61		
607-676-00	Mixture of: 2- methylnonanedioic acid;	423-670-1	—	Xi; R41 R43	Xi R: 41-43 S: (2-)24-26-37/39		

**Status:** EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

	2,4-dimethyl-4-methoxycarbonylundecanedioic acid; 2,4,6-trimethyl-4,6-dimethoxycarbonyltridecanedioic acid; 8,9-dimethyl-8,9-dimethoxycarbonylhexadecanedioic acid						
607-677-00-5	L-lysine	424-660-8		Xn; R48/22 Xi; R41 R43	Xn R: 41-43-48/22 S: (2-)22-26-36/37/39		
607-678-00-2	Mixture of: ethyl (2R,3R)-3-isopropylbicyclo[2.2.1]hept-5-ene-2-carboxylate; ethyl (2S,3S)-3-isopropylbicyclo[2.2.1]hept-5-ene-2-carboxylate	427-090-8		R43 N; R51-53	Xi; N R: 43-51/53 S: (2-)23-25-36/37-61		
607-679-00-8	Mixture of: 3-{5-[3-(4-{1,6-dihydro-2-hydroxy-4-methyl-1-[3-(methylammonio)propyl]-6-oxo-3-pyridylazo}benzamido)phenylazo]-1,2-dihydro-6-hydroxy-4-methyl-2-oxo-1-pyridyl}propyl(methyl)ammonium di(acetate); 3-{5-[4-(3-{1,6-	431-440-5		Xi; R41 N; R51-53	Xi; N R: 41-51/53 S: (2-)22-26-39-61		

*Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.*

	<p>dihydro-2-hydroxy-4-methyl-1-[3-(methylammonio)propyl]-6-oxo-3-pyridylazo}benzamido]phenylazo]-1,2-dihydro-6-hydroxy-4-methyl-2-oxo-1-pyridyl}propyl(dimethyl)ammonium di(acetate);</p> <p>3-{5-[3-(4-{1-[3-(dimethylammonio)propyl]-1,6-dihydro-2-hydroxy-4-methyl-6-oxo-3-pyridylazo}benzamido)phenylazo]-1,2-dihydro-6-hydroxy-4-methyl-2-oxo-1-pyridyl}propyl(dimethyl)ammonium di(acetate)</p>					
607-680-0028	<p>butyl(6-{2-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]vinyl}(4<i>S</i>,6<i>S</i>)-2,2-dimethyl[1,3]dioxan-4-yl)acetate</p>	432-810-9	—	R53	R: 53 S: 61	
607-681-0019	<p>Mixture of: 9-nonyl-10-octyl-19-carbonyloxyhexadecylnonadecanoic acid; 9-nonyl-10-octyl-19-carbonyloxyoctadecylnonadecanoic acid; dihexadecyl 9-</p>	432-910-2	—	R53	R: 53 S: 61	

*Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.*

	nonyl-10-octylnonadecandioate; 1-octadecyl,19-hexadecyl 9-nonyl-10-octylnonadecandioate; dioctadecyl 9-nonyl-10-octylnonadecandioate						
607-682-004	Complex mixture of Chinese gum rosin post reacted with acrylic acid	434-230-1144413-22953		R53	R: 53 S: 61		
607-683-001 X	Mixture of: methyl 3-((1E)-2-methylprop-1-enyl)-2,2-dimethylcyclopropanecarboxylate; methyl 3-((1Z)-2-methylprop-1-enyl)-2,2-dimethylcyclopropanecarboxylate (20:80)	435-450-0—		R43 N; R51-53	Xi; N R: 43-51/53 S: (2-)24-37-61		
607-684-001	Alkenes, C <sub>12-14</sub> , hydroformylation products, distn. residues, C-(hydrogen sulfobutanedioates), disodium salts	435-660-2243662-67015		Xi; R38 R43	Xi R: 38-43 S: (2-)24-37		

*Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.*

607-685-00	onium 2- cocoyloxyethanesulfonate	441-050-7	—	Xi; R38-41	Xi R: 38-41 S: (2-)26-37/39		
607-686-00	6,6'- bis(diazo-5,5',6,6'- tetrahydro-5,5'- dioxo) [methylene- bis(5-(6- diazo-5,6- dihydro-5- oxo-1- naphthylsulphonyloxy)-6- methyl-2- phenylene]di(naphthalene-1- sulfonate)	441-550-5	—	E; R2 F; R11 Carc. Cat. 3; R40	E; Xn R: 2-11-40 S: (2-)7-22-36/37		
607-687-00	Mixture of: 2- {3,6- bis-[(2- ethylphenyl)- methylamino]- xanthylum-9- yl}- benzenesulfonate (2-10 %); 2- {3,6- bis- [(2,3- dimethylphenyl)- methylamino]- xanthylum-9- yl}- benzenesulfonate (2-10 %); 2- {3,6- bis- [(2,4- dimethylphenyl)- methylamino]- xanthylum-9- yl}- benzenesulfonate (2-10 %); 2- {3,6- bis- [(2,5- dimethylphenyl)- methylamino]- xanthylum-9-	442-800-6	—	Xi; R38 N; R51-53	Xi; N R: 38-51/53 S: (2-)37-61		



**Status:** EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

yl}- benzenesulfonate (2-10 %); 2-{3- [(2,3- dimethylphenyl)- methylamino]-6- [(2- ethylphenyl)- methylamino]- xanthylum-9- yl}- benzenesulfonate (7-20 %); 2-{3- [(2,4- dimethylphenyl)- methylamino]-6- [(2- ethylphenyl)- methylamino]- xanthylum-9- yl}- benzenesulfonate (7-20 %); 2-{3- [(2,5- dimethylphenyl)- methylamino]-6- [(2- ethylphenyl)- methylamino]- xanthylum-9- yl}- benzenesulfonate (7-20 %); 2-{3- [(2,3- dimethylphenyl)- methylamino]-6- [(2,4- dimethylphenyl)- methylamino]- xanthylum-9- yl}- benzenesulfonate (7-20 %); 2-{3- [(2,3- dimethylphenyl)- methylamino]-6- [(2,5- dimethylphenyl)-							
--	--	--	--	--	--	--	--

*Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.*

	methylamino]-xanthylum-9-yl}-benzenesulfonate (7-20 %); 2-{3-[(2,4-dimethylphenyl)-methylamino]-6-[(2,5-dimethylphenyl)-methylamino]-xanthylum-9-yl}-benzenesulfonate (7-20 %)					
607-688-00	1-cyclohexa-1,4-dienyl-1-methoxycarbonylmethylammoniumchloride	444-320-2		Xn; R22	Xn R: 22 S: (2-)	
607-689-00	Mixture of: methyl 1,4-dimethylcyclohexanecarboxylate ('para-isomer' including <i>cis</i> - and <i>trans</i> -isomers); methyl 1,3-dimethylcyclohexanecarboxylate ('meta-isomer' including <i>cis</i> - and <i>trans</i> -isomers)	444-920-4		R52-53	R: 52/53 S: 61	
607-690-00	1,8-bis(methyl[2 <i>S</i> ,2 <i>S</i> ]-6,6,6'-tetramethoxy-2,2'-[ <i>N,N'</i> -bis(trifluoroacetyl)- <i>S,S'</i> -bi( <i>L</i> -homocysteinyloxy)diimino]dihexanoate	432-860-1	255387-4	R34	Xi R: 43 S: (2-)24-37	
607-691-00	Magnesium salts,	448-690-6		R53	R: 53 S: 61	

*Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.*

	fatty acids, C <sub>16-18</sub> and C <sub>18</sub> unsaturated, branched and linear						
607-692-00	Di-c salts, fatty acids, C <sub>16-18</sub> and C <sub>18</sub> unsaturated, branched and linear	446-470-4	—	R53	R: 53 S: 61		
607-693-00	Diethyl 2-(1-(diethylaminohydroxyphenyl)methanoyl)benzoate	443-860-6	302776-68	R53	R: 53 S: 61		
607-694-00 X	Diethyl 5,5-diphenyl-2-isoxazoline-3-carboxylate	443-870-0	163520-33	Xn, R22 R43 N; R50-53	Xn; N R: 22-43-50/53 S: (2-)22-36/37-60-61		
608-042-00	Diethyl 2,2-diphenyl-2-(3-pyrrolidinyl)acetonitrile hydrobromide	421-810-4	194602-27	Xn, R22 Xi; R41 R43 N; R51-53	Xn; N R: 22-41-43-51/53 S: (2-)24-26-37/39-61		
608-059-06 X	Di-amino-1-(2,6-dichloro-4-(trifluoromethyl)phenyl)-1H-pyrazole-3-carbonitrile	421-240-6	120068-79	N R51-53	N R: 51/53 S: 22-61		
608-060-06	Di-methyl-2-[(2-nitrophenyl)amino]-3-thiophenecarbonitrile	421-300-1	138564-59	N R50-53	N R: 50/53 S: 22-60-61		
608-062-00	Di-fluoro-4-hydroxybenzonitrile	422-810-7	82380-18	Xn, R22 Xi; R41 N; R51-53	Xn; N R: 22-41-51/53 S: (2-)22-26-39-61		

*Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.*

608-063-00	(S)- $\alpha$ -hydroxy-3-phenoxybenzeneacetonitrile	441-070-661826-76	441-070-661826-76	T; R25 Xi; R41 R43 N; R50-53	T; N R: 25-41-43-50/53 S: (1/2-)9-26-36/37/39-45-60-61		
608-064-00	7-azabenzothiazole	433-720-22	433-720-22	R52-53	R: 52/53 S: 61		
609-069-00	7- <i>tert</i> -butyl-3,5-dinitroacetophenone; 4- <i>tert</i> -butyl-2,6-dimethyl-4- <i>tert</i> -butylacetophenone; 4'- <i>tert</i> -butyl-2',6'-dimethyl-3',5'-dinitroacetophenone	201-328-981-14-1	201-328-981-14-1	Carc. Cat. 3; R40 N; R50-53	Xn; N R: 40-50/53 S: (2-)36/37-46-60-61		
611-154-00	5-benzamido-4-hydroxy-3-(4-methyl-2-sulfonatophenylazo)naphthalene-2,7-disulfonate	403-670-692408-46	403-670-692408-46	R52-53	R: 52/53 S: 61		
611-155-00	4,4'-oxybis(benzenesulfonylazide)	431-850-47456-68-0	431-850-47456-68-0	E; R3 F; R11 Xn; R48/22 N; R50-53	E; Xn; N R: 3-11-48/22-50/53 S: (2-)14-22-33-35-36-60-61		
611-156-00 X	4-[4-[7-(4-carboxylatoanilino)-1-hydroxy-3-sulfonato-2-naphthylazo]-2,5-dimethoxyphenylazo]benzoate	432-270-4221354-37	432-270-4221354-37	Repr. Cat. 3; R62 Xn; R48/22 N; R51-53	Xn; N R: 48/22-62-51/53 S: (2-)36/37-61		
611-157-00	benzenesulfonic acid, 3,3'-(methylenebis((dihydroxyphenylene)azo))bis-, potassium sodium salt; potassium sodium salt; 3-[(E)-	432-590-4243869-48	432-590-4243869-48	Xn; R36 R52-53	Xi R: 36-52/53 S: (2-)26-61		

**Status:** EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

	(6-{3,4-dihydroxy-2-[(Z)-(3-sulfonatophenyl)diazenyl]benzyl}-2,3-dihydroxyphenyl)diazenyl]benzenesulfonate					
611-158-00	Reaction mixture of: 2,3,4,2',3',4'-hexahydroxy-5,5'-diacetyl-diphenylmethane and 6-diazo-5,6-dihydro-5-oxo-1-naphthalenesulfonylchloride and 3-diazo-3,4-dihydro-6-methoxy-4-oxo-1-naphthalenesulfonylchloride	421-520-8	—	F; R11 R53	F R: 11-53 S: (2-)3-12-16-33-61	
611-159-00	Sodium 4-amino-6-((4-((4-(2,4-diaminophenyl)azo)phenylsulfamoyl)phenyl)azo)-5-hydroxy-3-((4-nitrophenyl)azo)naphthalene-2,7-disulfonate	421-880-6	—	Xi; R41 R52-53	Xi R: 41-52/53 S: (2-)26-39-61	
611-160-00	Mixture of: 1,1,1-tris(phenyl-4'-(3''-diazoo-3'',4''-dihydro-4''-oxo-naphthalene-1''-sulfonato)ethane; 1,1,1-tris(phenyl-4'-(6''-diazoo-5'',6''-dihydro-5''-oxo-naphthalene-1''-sulfonato)ethane;	422-760-6	—	F; R11 R53	F R: 11-53 S: (2-)3-12-33-61	

*Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.*

	reaction product of 1,1,1-tris( <i>p</i> -hydroxyphenyl)ethane with 6-diazo-5,6-dihydro-5-oxo-1-naphthylsulfonylchloride and 3-diazo-3,4-dihydro-4-oxo-1-naphthylsulfonylchloride (2:1); reaction product of 1,1,1-tris( <i>p</i> -hydroxyphenyl)ethane with 6-diazo-5,6-dihydro-5-oxo-1-naphthylsulfonylchloride and 3-diazo-3,4-dihydro-4-oxo-1-naphthylsulfonylchloride (1:2)						
611-161-00-7	Sodium [1,2'-(2-(8-amino-3,5-disulfonatonaphthalene)azo)-(4'-nitrobenzene)diolato- <i>O,O,N</i> ] [( <i>Z</i> )-2,2-((phenylcarbamoylprop-1'-enyl)azo)-5-sulfamoylbenzene]diolato- <i>O,O,N</i> ]chromate(III)	423-100-1	—	Xi; R41	Xi R: 41 S: (2-)26-39		
611-162-00-2	2-bis(((2-(dimethylammonio)ethyloxy)carbonyl)phenylazo)benzene-1,3-diolbis(methanesulfonate)	429-600-4	—	Xn; R22 Xi; R41 N; 2-R51-53	Xn; N R: 22-41-51/53 S: (2-)22-26-39-61		
611-163-00-8	2-bis(((2-(dimethylammonio)ethyloxy)carbonyl)phenylazo)benzene-1,3-diolbis(methanesulfonate)	429-610-9	—	Xn; R22 Xi; R41	Xn; N R: 22-41-51/53		

**Status:** EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

	ylazo)benzene-1,3-diol sulfate			N; R51-53	S: (2-)22-26-39-61		
611-164-00	Mixture of: 2,2'-dimethyl-2,2'-azobutanenitrile; 2-methylpentanenitrile-2-azo-2'-(2'-methylpropanenitrile); 2,2'-dimethyl-2,2'-azoheptanenitrile; 2-methylheptanenitrile-2-azo-2'-(2'-methylpropanenitrile); 2-methylheptanenitrile-2-azo-2'-(2'-methylbutanenitrile)	429-710-2	—	R10 R32 R44 Xn; R22 N; R51-53	Xn; N R: 10-22-32-44-51/53 S: (2-)12-15-16-47-51-61		
611-165-00	Mixture of: tetrasodium 4-amino-6-(5-(2,6-difluoropyrimidin-4-ylamino)-2-sulfonatophenylazo)-5-hydroxy-3-(4-(sulfatoethylsulfonyl)phenylazo)naphthalene-2,7-disulfonate; tetrasodium 4-amino-6-(5-(4,6-difluoropyrimidin-2-ylamino)-2-sulfonatophenylazo)-5-hydroxy-3-(4-(2-sulfatoethylsulfonyl)phenylazo)naphthalene-2,7-disulfonate	431-830-5	—	R52-53	R: 52/53 S: 61		
611-166-00	Mixture of:	432-100-9	—	Xi; R41 R52-53	Xi		

*Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.*

	pentasodium 4- amino-5- hydroxy-3- {(E)-4- [2- (sulfonatoxy)ethylsulfonyl]phenylazo}-6- {(E)-2- sulfonato-4- [2- (sulfonatoxy)ethylsulfonyl]phenylazo}naphthalene-2,7- disulfonate; tetrasodium 4- amino-5- hydroxy-3- {(E)-4- [2- (sulfonatoxy)ethylsulfonyl]phenylazo}-6- [(E)-2- sulfonato-4- (vinylsulfonyl)phenylazo]naphthalene-2,7- disulfonate; tetrasodium 4- amino-5- hydroxy-6- {(E)-2- sulfonato-4- [2- (sulfonatoxy)ethylsulfonyl]phenylazo}-3- [(E)-4- (vinylsulfonyl)phenylazo]naphthalene-2,7- disulfonate				R: 41-52/53 S: (2-)26-39-61	
611-167-00 X	odium bis[tris(2- hydroxyethyl)ammonium] [6- anilino-4'- (4,8- disulfonato-2- naphthylazo)-5'- methyl-3- sulfonato]naphthalene-2- azobenzene-1,2'- diolato]cuprate(II)	435-240-9—	R52-53	R: 52/53 S: 61		
611-168-00	mixture of: 3- [[4- chloro-6- [[7- [(1,5-	435-440-6—	Xi, R41	Xi R: 41 S: (2-)22-26-39		



**Status:** EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

	disulfo-2-naphthalenyl)azo]-8-hydroxy-3,6-disulfo-1-naphthalenyl]amino]-1,3,5-triazin-2-yl]amino]-5-[[4-chloro-6-[[8-hydroxy-3,6-disulfo-7-[(2-sulfo-phenyl)azo]-1-naphthalenyl]amino]-1,3,5-triazin-2-yl]amino]benzoic acid; 3,5-bis[[4-chloro-6-[[7-[(1,5-disulfo-2-naphthalenyl)azo]-8-hydroxy-3,6-disulfo-1-naphthalenyl]amino]-1,3,5-triazin-2-yl]amino]benzoic acid					
611-169-00	Sodium 5-(2-carboxyphenylazo)-6-hydroxynaphthalene-2-sulfonate	435-800-2	—	R52-53	R: 52/53 S: 61	
611-170-00	Mixture of: trisodium 2-((1-(2-hydroxy-κ-O-5-(2-sulfonatoethansulfonyl)phenylazo)-κ-N <sup>2</sup> )-1-phenylmethyl)azo-κ-N <sup>1</sup> )-4-sulfonatobenzoate(5-)-κ-O)cuprate(II); disodium 2-((1-(5-	435-880-9	—	R52-53	R: 52/53 S: 22-61	

*Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.*

	ethenesulfonyl-2-hydroxy- $\kappa$ -O-phenylazo- $\kappa$ -N <sup>2</sup> )-1-phenylmethyl)azo- $\kappa$ -N <sup>1</sup> )-4-sulfonatobenzoate- $\kappa$ -O-(5-)cuprate(II)					
611-171-00	Mixture of: trisodium 3-(5-(2,6-difluoropyrimidin-4-ylamino)-2-sulfonatophenylazo)-5-(4-fluoro-6-morpholin-4-yl-1,3,5-triazin-2-ylamino)-4-hydroxy-2,7-naphthalenedisulfonate; trisodium 3-(5-(4,6-difluoropyrimidin-2-ylamino)-2-sulfonatophenylazo)-5-(4-fluoro-6-morpholin-4-yl-1,3,5-triazin-2-ylamino)-4-hydroxy-2,7-naphthalenedisulfonate	436-890-6	—	Xi; R41 R52-53	Xi R: 41-52/53 S: (2-)22-26-39-61	
611-172-00	Mixture of: triammonium 6-amino-3-((2,5-diethoxy-4-(3-phosphonophenyl)azo)phenyl)azo-4-hydroxy-2-naphthalenesulfonate;	438-310-7	—	E; R2 Repr. Cat. 3; R62 Xn; R22-48/22 R52-53	E; Xn R: 2-22-48/22-62-52/53 S: (2-)22-35-36/37-61	

**Status:** EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

	diammonium 3-((4- (7- amino-1- hydroxy-3- sulfo- naphthalen-2- yl)azo)-2,5- diethoxyphenyl)azo)benzoate					
611-173-00	Mixture of: 3-[3- carbamoyl-5- (5-{4- chloro-6- [4-(2- sulfonatooxyethylsulfonyl)anilino]-1,3,5- triazin-2- ylamino)-2- sulfonatophenylazo]-1,2- dihydro-6- hydroxy-4- methyl-2- oxo-1- pyridyl]propanoic acid, trisodium salt; 3-[3- carbamoyl-5- (5-{4- chloro-6- [4- (vinylsulfonyl)anilino]-1,3,5- triazin-2- ylamino)-2- sulfonatophenylazo]-1,2- dihydro-6- hydroxy-4- methyl-2- oxo-1- pyridyl]propanoic acid, disodium salt	440-510-4	—	Xi; R41 R43	Xi R: 41-43 S: (2-)22-26-36/37/39	
611-174-00	Mixture of: 3- [5-(4- ethenesulfonylbutyrylamino)-2- sulfophenylazo]-5- {4- chloro- [6-(4-(3-	442-290-5	5457624-8	Xi; R41	Xi R: 41 S: (2-)22-26-39	

*Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.*

	amino-5-hydroxy-2,7-disulfonaphthalene-4-ylazo)-3-sulfophenylamino]-1,3,5-triazin-2-ylamino)-4-hydroxynaphthalene-2,7-disulfonic acid, sodium salt; 3-[5-(4-(2-chloroethanesulfonyl)butyrylamino)-2-sulfophenylazo]-5-{4-chloro-[6-(4-(3-amino-5-hydroxy-2,7-disulfonaphthalene-4-ylazo)-3-sulfophenylamino)-1,3,5-triazin-2-ylamino)-4-hydroxynaphthalene-2,7-disulfonic acid, sodium salt					
611-175-00	mixture of: trisodium 5-{4-chloro-6-[N-ethyl-(3-(2-sulfonatooxy)ethylsulfonyl)anilino]-1,3,5-triazin-2-ylamino)-4-hydroxy-3-[4-(vinylsulfonyl)phenylazo]naphthalene-2,7-disulfonate; trisodium 5-{4-chloro-6-[N-ethyl-3-(vinylsulfonyl)anilino]-1,3,5-	444-050-5	—	Xi; R41 R52-53	Xi R: 41-52/53 S: (2-)22-26-39-61	

**Status:** EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

	triazin-2-ylamino}-4-hydroxy-3-[4-(2-(sulfonatooxy)ethylsulfonyl)phenylazo]naphthalene-2,7-disulfonate; disodium 5-{4-chloro-6-[N-ethyl-3-(vinylsulfonyl)anilino]-1,3,5-triazin-2-ylamino}-4-hydroxy-3-[(4-(vinylsulfonyl)phenylazo]naphthalene-2,7-disulfonate; tetrasodium 5-{4-chloro-6-[N-ethyl-3-(2-(sulfonatooxy)ethylsulfonyl)anilino]-1,3,5-triazin-2-ylamino}-3-[4-(2-(sulfonatooxy)ethylsulfonyl)phenylazo]-4-hydroxynaphthalene-2,7-disulfonate					
611-176-00-0	bis(2,3,4-trihydroxybenzyl)-p-cresol ester with 6-diazo-5,6-dihydro-5-oxo-1-naphthalenesulfonate	444-250-2—		E; R2 F; R11 N; R51-53	E; N R: 2-11-51/53 S: (2-)22-61	
611-177-00-0	mixture of: pentasodium bis[6-anilino-3,5'-disulfonatonaphthalene-2-azobenzene-1,2'-diolato]cobaltate(III); tetrasodium [6-anilino-3,5'-	444-290-0508202-43	0508202-43	Xi; R41 R43 R52-53	Xi R: 41-43-52/53 S: (2-)22-24-26-37/39-61	

*Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.*

	disulfonatonaphthalene-2-azobenzene-1,2'-diolato] [6-anilino-5'-sulfamoyl-3-sulfonatonaphthalene-2-azobenzene-1,2'-diolato]cobaltate(III); trisodium bis[6-anilino-5'-sulfamoyl-3-sulfonatonaphthalene-2-azobenzene-1,2'-diolato]cobaltate(III)					
611-178-00 X	mixture of: pentasodium 4-amino-5-hydroxy-3- {(E)-4- [2- (sulfonatooxy)ethylsulfonyl]phenylazo}-6- {(E)-2- sulfonato-4- [2- (sulfonatooxy)ethylsulfonyl]phenylazo}naphthalene-2,7- disulfonate; tetrasodium 4-amino-5-hydroxy-3- {(E)-4- [2- (sulfonatooxy)ethylsulfonyl]phenylazo}-6- [(E)-2- sulfonato-4- (vinylsulfonyl)phenylazo]naphthalene-2,7- disulfonate; tetrasodium 4-amino-5-hydroxy-6- [(E)-2- sulfonato-4- [2- (sulfonatooxy)ethylsulfonyl]phenylazo}-3- [(E)-4- (vinylsulfonyl)phenylazo]naphthalene-2,7- disulfonate;	445-280-9	—	Xi; R41 R43 R52-53	Xi R: 41-43-52/53 S: (2-)24-26-37/39-61	

**Status:** EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

	trisodium 4- amino-5- hydroxy-3- [(E)-4- (vinylsulfonyl)phenylazo]-6- [(E)-2- sulfonato-4- (vinylsulfonyl)phenylazo]naphthalene-2,7- disulfonate; trisodium 4- amino-5- hydroxy-3- [(2- hydroxyethylsulfonyl)- phenylazo]-6- [(E)-2- sulfonato-4- (vinylsulfonyl)phenylazo]naphthalene-2,7- disulfonate; trisodium 4- amino-5- hydroxy-3- [(E)-4- (vinylsulfonyl)phenylazo]-6- [-2- sulfonato-4- (2- hydroxyethylsulfonyl)phenylazo]naphthalene-2,7- disulfonate					
611-179-00	mixture of: pentasodium 2-[[8- [[4- chloro-6- [[4-(2- sulfonato ethylsulfonyl)]phenyl]amino]-1,3,5- triazin-2- yl]amino-1- hydroxy-3,6- disulfonato-2- naphthalenyl]azo]naphthalene-1,5- disulfonate; 2-[[8- [[4- chloro-6- [[4-[[2- ethenyl]sulfonyl]phenyl]amino]-1,3,5-	450-010-8	—	Xi; R41 R43	Xi R: 41-43 S: (2-)22-24-26-37/39	

*Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.*

	triazin-2-yl]amino]-1-hydroxy-3,6-disulfonato-2-naphthalenyl]azo]naphthalene-1,5-disulfonate						
611-180-00-00	on, complexes with diazotised 4-aminobenzenesulfonamide, diazotised 3-aminobenzenesulfonic acid, diazotised 3-amino-4-hydroxybenzenesulfonamide, diazotised 3-amino-4-hydroxy-N-phenylbenzenesulfonamide, diazotised 5-amino-2-(phenylamino)benzenesulfonic acid and resorcinol, sodium salts		417-850-7	—	N; R51-53	N R: 51/53 S: 22-61	
612-238-00-38	B chloro-2-hydroxypropyl) trimethylammonium chloride ... %		222-048-3	3327-22-8	Carc. Cat. 3, R40 R52-53	Xn R: 40-52/53 S: 36/37-61	
612-239-00-31	phenyl-3,3',4,4'-tetrayltetraamine; diaminobenzidine		202-110-6	91-95-2	Carc. Cat. 2; R45 Muta. Cat. 3; R68	T R: 45-68 S: 53-45	
612-240-00-91	primethanil (ISO); N-(4,6-dimethylpyrimidin-2-yl)aniline		—	53112-28-0	N; R51-53	N R: 51/53 S: 61	



*Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.*

612-241-00	piperazine hydrochloride; [1] piperazine dihydrochloride; [2] piperazine phosphate [3]	228-042-7 205-551-2 217-775-8	6094-40-2 122-64-3 1931-97-9	Repr. Cat. 3; R62-63 Xi; R36/38 R42/43 R52-53	Xn R: 36/38-42/43-62-63-52/53 S: (1/2-)22-36/37-45-63-61		
612-242-00 X	pyprodinil (ISO); 4-cyclopropyl-6-methyl-N-phenylpyrimidin-2-amine	—	121552-6	R43 N; R50-53	Xi; N R: 43-50/53 S: (2-)24-37-40-60-61	C ≥ 2,5 %: Xi, N; R43-50/53 < 2,5 %: Xi, N; R43-51/53 0,25 % ≤ C < 1 %: N; R51/53 0,025 % ≤ C < 0,25 %: R52/53	
612-243-00	15-cis-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine 2-hydroxy-2-phenylacetate	420-560-3 79617-97		Xi; R41 N; R50-53	Xi; N R: 41-50/53 S: (2-)26-39-60-61	C ≥ 10 %: Xi, N; R41-50/53 < 10 %: Xi, N; R36-50/53 2,5 % ≤ C < 5 %: N; R50/53 0,25 % ≤ C < 2,5 %: N; R51/53 0,025 % ≤ C < 0,25 %: R52/53	
612-244-00-0	(piperazin-1-yl)-benzo[d]isothiazole hydrochloride	421-310-6 687691-88		Repr. Cat. 3; R62 Xn; R22 Xi; R36 R43 N; R50-53	Xn; N R: 22-36-43-62-50/53 S: (2-)22-26-36/37/39-60-61		

*Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.*

612-245-00-6			421-460-219398-06	Carc. Cat. 3; R40 T; R48/25 Xn; R22 Xi; R41 R43 N; R50-53	T; N R: 22-40-41-43-48/25-50/53 S: (1/2-)22-24-37/39-45-60-61	C ≥ 25 %: R22-40-41-43-48/25-50/53 ≤ C < 25 %: T, N; R40-41-43-48/25-50/53 5 % ≤ C < 10 %: Xn, N; R36-40-43-48/22-50/53 2,5 % ≤ C < 5 %: Xn, N; R40-43-48/22-50/53 1 % ≤ C < 2,5 %: Xn, N; R40-43-48/22-51/53 0,25 % ≤ C < 1 %: N; R51/53 0,025 % ≤ C < 0,25 %: R52/53	
612-246-00-24	E		429-740-640722-80	Carc. Cat. 2; R45 Muta. Cat. 2; R46 Xn; R48/22 R43 R52-53	T R: 45-46-43-48/22-52/53 S: 53-45-61		
612-247-00-73			423-530-8152828-2314	T R48/25 Xn; R22 R52-53	T R: 22-48/25-52/53 S: (1/2-)22-36-45-61		
612-248-00-2			439-540-0	Xi; R38 R43 R53	Xi R: 38-43-53 S: (2-)24-37-61		

*Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.*

	alkenes, branched (C <sub>8-10</sub> , C <sub>9</sub> -rich)						
612-249-00-8	(3-chlorophenyl) (1H-imidazol-1-yl)methyl]-1,2-benzenediamine dihydrochloride	425-030-5	159939-8	5R2 Repr. Cat. 3; R62 Xn; R22 C; R34 R43 N; R51-53	C; N R: 22-34-43-62-51/53 S: (1/2-)22-26-36/37/39-45-61		
612-250-00-1	bis(bromo-N,N-dimethylformiminium chloride	425-970-6	3724-43-4	R14 Repr. Cat. 2; R61 Xn; R22 C; R35	T; C R: 61-14-22-35 S: 53-45		
612-251-00-9	1-(3-chloroallyl)-3,5,7-triaza-1-azoniaadamantane chloride	426-020-3	51229-78	Xn; R11 Repr. Cat. 3; R63 Xn; R22 Xi; R38 R43 N; R51-53	F; Xn; N R: 11-22-38-43-63-51/53 S: (2-)7-22-33-36/37-61		
612-252-00-1	imidacloprid (ISO); 1-(6-chloropyridin-3-ylmethyl)-N-nitroimidazolidin-2-ylidenamine	428-040-8	138261-4	Xn; R22 N; R50-53	Xn; N R: 22-50/53 S: (2-)22-57-60-61		
612-253-00-X	1-methoxy-6-(3-morpholin-4-yl-propoxy)-3H-quinazolin-4-one; [containing < 0,5 % formamide (EC No 200-842-0)]	429-400-7	199327-6	R52-53	R: R52/53 S: 61		

*Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.*

612-253-07	7-methoxy-6-(3-morpholin-4-yl-propoxy)-3H-quinazolin-4-one; [containing $\geq 0,5$ % formamide (EC No 200-842-0)]	429-400-7	199327-6	IR2pr. Cat. 2; R61 R52-53	T R: 61-52/53 S: 53-45-61		
612-254-06	Reaction products of diisopropanolamine with formaldehyde (1:4)	432-440-8	220444-7	Carc. Cat. 3; R40 Xn; R22 C; R34 R43 N; R51-53	C; N R: 22-34-40-43-51/53 S: (1/2-)13-25-26-36/37/39-45-61		
612-255-00	3-methoxypropyl)-4-piperidinamine	431-950-8	179474-7	Xn; R21/22 C; R34 R52-53	C R: 21/22-34-52/53 S: (1/2-)26-36/37/39-45-61		
612-256-06	Benzyl(S)-2-[(2'-cyanobiphenyl-4-ylmethyl)pentanoylamino]-3-methylbutyrate	427-470-3	137864-2	Xn; R22 R43	Xn R: 22-43 S: (2-)36/37		
612-257-00	Tripropylammonium dihydrogenphosphate	433-700-3	35687-90	Xn; R22	Xn R: 22 S: (2-)22		
612-259-00	2-ethyl-3-trimethoxysilyl-2-methyl-propanamine	437-720-3	227085-5	Xi; R41	Xi R: 41 S: (2-)26-39		
612-261-00	5-dichloro-2-fluoro-4-(1,1,2,3,3,3-hexafluoropropoxy)aniline	441-190-9	121451-0	Xn; R22 R43 N; R50-53	Xn; N R: 22-43-50/53 S: (2-)24-37-40-41	C $\geq$ 25 %: Xn, N; R22-43-50/53 0,5-1 %: $\leq C < 25$ %: Xi, N; R43-50/53 1 % $\leq C < 2,5$ %:	

*Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.*

							Xi, N; R43-51/53 0,25 % ≤ C < 1 %: N; R51/53 0,025 % ≤ C < 0,25 %: R52/53
612-265-00-5	(2-hydroxyethyl)-(2-hydroxypropyl)ammonium acetate	444-360-0191617-13	444-360-0191617-13	—	R52-53	R: 52/53 S: 61	
612-266-00-0	4-chloro-(3-fluorobenzoyloxy)aniline	445-590-4202197-26	445-590-4202197-26	—	Muta. Cat. 3; R68 Xn; R22-48/22 N; R50-53	Xn; N R: 22-48/22-68-50/53 S: (2-)22-36/37-60-61	
612-267-00-6	(hydrogenated tallow C <sub>16-18</sub> -alkyl)hydroxylamine	418-370-0—	418-370-0—	—	R43 R53	Xi R: 43-53 S: (2-)36/37-61	
612-269-00-7	Mixture of: 1-[di(4-octylphenyl)aminomethyl]-5-methyl-1H-benzotriazole; 1-[di(4-octylphenyl)aminomethyl]-4-methyl-1H-benzotriazole; mixture of: N-[(5-methyl-1H-benzotriazol-1-yl)methyl]-4-octyl-N-(4-octylphenyl)aniline; N-[(4-methyl-1H-benzotriazol-1-yl)methyl]-4-octyl-N-	420-720-2—	420-720-2—	—	R53	R: 53 S: 22-61	

*Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.*

	(4-octylphenyl)aniline						
612-270-0052	azetidine-2-carboxylic acid 4-cyanobenzamide hydrochloride	433-010-2	—	Xn; R22 R43 R52-53	Xn R: 22-43-52/53 S: (2-)22-36/37-61		
612-271-0018	mixture of: ethyl 2-((4-(5,6-dichlorobenzothiazol-2-ylazo)phenyl)ethylamino)benzoate; ethyl 2-((4-(6,7-dichlorobenzothiazol-2-ylazo)phenyl)ethylamino)benzoate	434-970-5	160987-5	R53	R: 53 S: 61		
612-272-0013	onium (η-6-2-(2-(1,2-dicarboxylatoethylamino)ethylamino)butane-1,4-dioato(4-))iron(3+) monohydrate	435-210-5	—	N; R51-53	N R: 51/53 S: 61		
612-273-0019	oil), bis(2-hydroxyethyl)ammonium fluoride	435-650-8	—	Xn; R22 C; R35 N; R50-53	C; N R: 22-35-50/53 S: (1/2-)26-36/37/39-45-60-61		
612-274-0045	[2-amino-1(4-methoxyphenyl)ethyl]cyclohexanol acetate	445-750-3	—	Xn; R22 Xi; R41 R43 R52-53	Xn R: 22-41-43-52/53 S: (2-)22-24-26-37/39-61		
612-275-001X	fatty acids, C <sub>18</sub> -unsatd., dimers, reaction products with 1-piperazineethanamine and tall oil	447-880-6	206565-8	Xi; R38-41 R43 N; R50-53	Xi; N R: 38-41-43-50/53; S: (2-)23-26-30/37/39-60-61 ≤ C < 20 %: Xi, N; R41-43-50/53 5 % ≤ C < 10 %: Xi, N; R36-43-50/53 2,5 % ≤ C < 5 %:		

*Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.*

						Xi, N; R43-50/53 1 % ≤ C < 2,5 %: Xi, N; R43-51/53 0,25 % ≤ C < 1 %: N; R51/53 0,025 % ≤ C < 0,25 %: R52/53
612-276-00-5	amino-4- [(4- amino-2- sulfofenyl)amino]-9,10- dihydro-9,10- dioxo-2- anthracenesulfonic acid, disodium salt, reaction products with 2-[[3- [(4,6- dichloro-1,3,5- triazin-2- yl)ethylamino]phenyl]sulfonyl]ethyl hydrogen sulfate, sodium salts	451-430-4500717-3	6X1; R41 R43 R52-53	Xi R: 41-43-52/53 S: (2-)22-24-26-36/37/39-61		
612-277-00-0	Mixture of: 4- amino-3- (4- ethenesulfonyl-2- sulfonatophenylazo)-5- hydroxy-6- (5-{4- chloro-6- [4-(2- sulfonatooxyethanesulfonyl)phenylamino]-1,3,5- triazin-2- ylamino}-2- sulfonatophenylazo)naphthalene-2,7- disulfonate	451-440-9586372-44	6X1; R41	Xi R: 41 S: (2-)22-26-39		

*Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.*

	potassium/ sodium; 4- amino-5- hydroxy-6- (5-{4- chloro-6- [4-(2- sulfonooxyethanesulfonyl)phenylamino]-1,3,5- triazin-2- ylamino}-2- sulfonatophenylazo)-3- (2- sulfonato-4- (2- sulfonooxyethanesulfonyl)phenylazo)naphthalene-2,7- disulfonate potassium/ sodium						
612-278-00	imidium bromide; 3,8- diamino-1- ethyl-6- phenylphenantridinium bromide		214-984-61239-45-8	Muta. Cat. 3; R68 T+; R26 Xn; R22	T+ R: 22-26-68 S: (1/2-)28-36/37-45-63		
612-279-00	(R,S)-2- amino-3,3- dimethylbutane amide		447-860-7144177-62	Repr. Cat. 3; R62 Xn; R48/22 Xi; R36/38 R43	Xn R: 36/38-43-48/22-62 S: (2-)22-26-36/37		
612-280-00	7 amino-9- ethyl carbazole; 9- ethylcarbazol-3- ylamine	H	205-057-7132-32-1	Carc. Cat. 2; R45	T R: 45 S: 53-45		
613-116-00	tolylfluamid (ISO); dichloro- <i>N</i> - [(dimethylamino)sulphonyl]fluoro- <i>N</i> - ( <i>p</i> - tolyl)methanesulphenamide; [containing < 0,1 % (w/w) of particles		211-986-9731-27-1	Xi; R36/37/38 R43 N; R50	Xi; N R: 36/37/38-43-50; S: (2-)25-36/37-46-61	C ≥ 20 %: Xi, N; R36/37/38-43-50 ≤ C < 20 %: Xi, N; R43-50	



*Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.*

	with an aerodynamic diameter of below 50 µm]						1 % ≤ C < 2,5 %: Xi; R43
613-280-00-X	tetrahydro-1,3-dimethyl-1H-pyrimidin-2-one; dimethyl propyleneurea	230-625-6	7226-23-5	Repr. Cat. 3; R62 Xn; R22 Xi; R41	Xn R: 22-41-62 S: 26-36/37/39		
613-281-00	quinoline E	202-051-6	91-22-5	Carc. Cat. 2; R45 Muta. Cat. 3; R68 Xn; R21/22 Xi; R36/38 N; R51-53	T; N R: 45-21/22-36/38-68-51/53 S: 53-45-61		
613-282-00-01	iconazole (ISO); (RS)-(E)-5-(4-chlorobenzylidene)-2,2-dimethyl-1-(1H-1,2,4-triazol-1-yl)methyl)cyclopentanol	—	131983-72-7	N; R51-53	N R: 51/53 S: 61		
613-283-00-01	iconazole; 1-[4-[[[(2SR,4RS)-2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]ethanone	265-667-4	65277-42-1	Repr. Cat. 2; R60 T; R25 Xn; R48/22 N; R50-53	T; N R: 60-25-48/22-50/53 S: 53-45-60-61		
613-284-00-01	iconazole (ISO); (1RS,5RS;1RS,5SR)-5-(4-chlorobenzyl)-2,2-dimethyl-1-(1H-1,2,4-	—	125116-23-3	Repr. Cat. 3; R63 Xn; R22 N; R51-53	Xn; N R: 22-63-51/53 S: (2-)36/37-46-61		



*Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.*

613-288-00-3-	bis(dimethylcarbamoyl)-imidazolium chloride	420-930-4135756-6	Xn; R22 Xi; R41 R52-53	Xn R: 22-41-52/53 S: (2-)22-26-37/39-61
613-289-00-04-	chloro-2-fluoro-5-methylphenyl)-1-methyl-5-(trifluoromethyl)-1H-pyrazole	432-020-4142623-48	N R50-53	N R: 50/53 S: 60-61
613-290-00-4	hydroxy-7-(2-aminoethyl)-1,3-benzothiazol-2(3H)-one hydrochloride	432-470-1189012-93	Xn; R41 R43 N; R50-53	Xi; N R: 41-43-50/53 S: (2-)24-26-37/39-60-61
613-291-00-4- X	4-dihydro-4-(4-(4-hydroxyphenyl)-1-piperazinyl)phenyl)-2-(1-methylpropyl)-3H-1,2,4-triazol-3-one	434-820-9106461-4	Xn; R48/22 N; R50-53	Xn; N R: 48/22-50/53 S: (2-)22-36-60-61
613-292-00-5',N	"-tris(2-methyl-2,3-epoxypropyl)-perhydro-2,4,6-oxo-1,3,5-triazine	435-010-826157-73	Muta. Cat. 3; R68 R52-53	Xn R: 68-52/53 S: (2-)36/37-61
613-293-00-0	(4-tert-butylphenyl)-6-cyano-5-[bis(ethoxycarbonylmethyl)carbamoyloxy]-1H-pyrrolo[1,2-b][1,2,4]triazole-7-carboxylic acid 2,6-di-tert-butyl-4-methylcyclohexylester	448-050-6444065-1	R63	R: 53 S: 61

*Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.*

613-294-00-6	hexyldecanoic acid [4-(6-tert-butyl-7-chloro-1H-pyrazolo[1,5-b][1,2,4]triazol-2-yl)phenylcarbamoyl]methylester	448-260-8379268-96953	R53	R: 53 S: 61		
613-295-00-11	amino-3-chloro-6,11-dihydro-5,5-dioxo-6-methyl-dibenzo[c,f][1,2]thiazepine hydrochloride	448-720-8363138-44693	Xn; R22 Xi; R41 R52-53	Xn R: 22-41-52/53 S: (2-)22-26-39-61		
613-296-00-07	pentapotassium 2-(4-(5-[1-(2,5-disulfonatophenyl)-4,5-dihydro-3-methylcarbamoyl-5-oxopyrazol-4-ylidene]-3-methyl-1,3-pentadienyl)-3-methylcarbamoyl-5-oxidopyrazol-1-yl)benzene-1,4-disulfonate	418-270-7—	R43 R52-53	Xi R: 43-52/53 S: (2-)24-37-47-61		
613-297-00-22	(6-bromophenyl)-2-tert-butyl-2H-tetrazole	420-820-6—	R10 Xn; R22 N; R51-53	Xn; N R: 10-22-51/53 S: (2-)16-61		
613-298-00-18	(6-hydroxy-4-methyl-5-(3-methylimidazolium-1-yl)-3-(4-phenylazo)-1H-pyridin-2-one)ethylene dilactate	421-560-6—	Xn; R48/22 Xi; R41 N; R51-53	Xn; N R: 41-48/22-51/53 S: (2-)22-26-36/39-61		
613-299-00-03	main component	422-610-1—	Xi; R41	Xi R: 41		

**Status:** EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

1 (isomer 1): 2-{6- fluoro-4- [3-(2,5- disulfo- phenylazo)-4- hydroxy-2- sulfonaphth-7- ylamino]-1,3,5- triazin-2- ylamino}-3- {6- fluoro-4- [3-(1,5- disulfonaphth-2- ylazo)-4- hydroxy-2- sulfonaphth-7- ylamino]-1,3,5- triazin-2- ylamino}- propane sodium salt; main component					S: (2-)22-26-39	
1 (isomer 2): 2-{6- fluoro-4- [3-(2,5- disulfo- phenylazo)-4- hydroxy-2- sulfonaphth-7- ylamino]-1,3,5- triazin-2- ylamino}-3- {6- fluoro-4- [3-(2,5- disulfo- phenylazo)-4- hydroxy-2- sulfonaphth-7- ylamino]-1,3,5- triazin-2- ylamino}- propane sodium salt;						

*Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.*

	main component 2: 2,3-bis-{6-fluoro-4-[3-(2,5-disulfo-phenylazo)-4-hydroxy-2-sulfonaphth-7-ylamino]-1,3,5-triazin-2-ylamino}-propane sodium salt; main component 3: 2,3-bis-{6-fluoro-4-[3-(1,5-disulfonaphth-2-ylazo)-4-hydroxy-2-sulfonaphth-7-ylamino]-1,3,5-triazin-2-ylamino}-propane sodium salt						
613-300-00-7	imidazol-1-yl-octadecan-2-ol	434-120-3	—	R43 R53	Xi R: 43-53 S: (2-)24-37-61		
613-301-00-2	dimethyl-1-{{[2-methoxy-5-(2-methyl-butoxycarbonyl)phenylcarbonyl]-[2-octadecyl-1,1-dioxo-1,2,4-benzothiadiazin-3-yl]methyl}imidazole-4,5-dicarboxylate	443-910-7	—	R53	R: 53 S: 61		

*Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.*

613-302-00	Disodium 2-(5- carbamoyl-1- ethyl-2- hydroxy-4- methyl-6- oxo-1,6- dihydro- pyridine-3- ylazo)-4- (4- fluoro-6- (4-(2- sulfonyloxy- ethylsulfonyl)- phenylamino)-1,3,5- triazine-2- ylamino)benzene sulfonate	432-980-4243858-60	Xn; R41	Xi R: 41 S: (2-)22-26-39		
613-303-00	β1- methyl-2- (4- phenoxyphenoxy)ethoxy)pyridine	429-800-195737-68	N; R50-53	N R: 50/53 S: 60-61		
613-304-00	2,3- dihydroxy-2,3- dihydro-1 <i>H</i> - indolium bromide	421-170-6138937-28	Xn; R22 Xi; R41	Xn R: 22-41 S: (2-)22-26-39		
613-305-00	4- hydroxy-4- octyloxyphenyl)-2 <i>H</i> - benzotriazole	448-630-93147-77-1	R53	R: 53 S: 61		
613-306-00 X	2,5- dioxopyrrolidin-1- yl)-9 <i>H</i> - fluoren-9- ylmethyl carbonate	433-520-582911-69	Xn; R22 R43 N; R51-53	Xn; N R: 22-43-51/53 S: (2-)24-37-61		
613-307-00	5-thianidin (ISO); 3-[(2- chloro-1,3- thiazol-5- yl)methyl]-2- methyl-1- nitroguanidine	—	210880-92	Xn; R22 N; R50-53	Xn; N R: 22-50/53 S: (2-)46-60-61 C ≥ 25 %: Xn, N; R22-50/53 0,5 % ≤ C < 25 %: N; R50/53 0,25 % ≤ C < 2,5 %:	

*Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.*

						N; R51/53 0,025 % ≤ C < 0,25 %: R52/53	
613-308-00-0	amino-5-methylthiazole	423-800-57305-71-7		Xn; R22-48/22 N; R50-53	Xn; N R: 22-48/22-50/53 S: (2-)22-36-60-61		
613-309-00-6	methyl-3-phenyl-1-piperazine	431-180-25271-27-2		Xn; R21/22 Xi; R38-41 R52-53	Xn R: 21/22-38-41-52/53 S: (2-)26-36/37/39-61		
613-310-00-1	(3 <i>S</i> ,4 <i>R</i> )-4-(4-fluorophenyl)-3-(3,4-methylenedioxyphenoxy)methyl)- <i>N</i> -benzylpiperidine hydrochloride	432-360-3105813-13-3		Xn; R22 R43 N; R50-53	Xn; N R: 22-43-50/53 S: (2-)22-24-37-60-61		
613-311-00-7	methyl-5-nitrophenyl-guanidine	435-500-1152460-07-7		Xn; R22 Xi; R36 R43 R52-53	Xn R: 22-36-43-52/53 S: (2-)22-24-26-37-61		
613-312-00-24	methyl-2-phenyl-1-piperazinyl)benzenemethanol monohydrochloride	420-200-5—		Xn; R22 Xi; R41 R43 R52-53	Xn R: 22-41-43-52/53 S: (2-)22-26-36/37/39-61		
613-313-00-84	(4-(3-pyridinyl)-1 <i>H</i> -imidazol-1-yl)butyl)-1 <i>H</i> -isoindole-1,3(2 <i>H</i> )-dione	442-780-9173838-67-8		R52-53	R: 52/53 S: 61		
613-314-00-3	decyloxazolidin-2-one; 4-decyl-1,3-oxazolidin-2-one	443-770-77693-82-5		N; R50-53	N R: 50/53 S: 22-24-60-61		



*Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.*

613-315-00	009 Potassium 4-[5-[3-carboxylato-4,5-dihydro-5-oxo-1-(4-sulfonatophenyl)pyrazol-4-ylidene]-3-(piperidinocarbonyl)penta-1,3-dienylidene]-5-hydroxy-1-(4-sulfonatophenyl)pyrazole-3-carboxylate	430-390-1	—	Xn; R20 R52-53	Xn R: 20-52/53 S: (2-)25-61		
613-316-00	014 tri(3-methylpropylaziridinylpropanoate); (TAZ)	257-765-0	52234-82	Muta. Cat. 3; R68 Xi; R41 R43	Xn R: 41-43-68 S: 26-36/37/39-42		
615-044-00	001 chlorophenylisocyanate	203-176-9	104-12-1	T+; R26 Xn; R22 Xi; R37/38-41 R42 N; R50-53	T+; N R: 22-26-37/38-41-42-50/53 S: (1/2-)26-28-36/37/39-45-63-60-61		
615-045-00	007'-methylene bis(3-chloro-2,6-diethylphenylisocyanate)	420-530-1	—	R42/43 R53	Xn R: 42/43-53 S: (2-)23-24-37-45-61		
616-126-00	00X methyl-4-nitro-3-propyl-1H-pyrazole-5-carboxamide	423-960-6	139756-0	Xn; R22-48/22 R52-53	Xn R: 22-48/22-52/53 S: (2-)22-36/37-61		
616-164-00	017 Dinoxystrobin (ISO); (E)-2-(methoxyimino)-N-methyl-2-[α-(2,5-xilyloxy)-o-tolyl]acetamide	—	149961-5	2C4 Carc. Cat. 3; R40 Repr. Cat. 3; R63 Xn; R20 N; R50-53	Xn; N R: 20-40-63-50/53 S: (2-)36/37-40/60-61 < 25 %: Xn, N; R40-63-50/53 2,5 % ≤ C < 5 %: Xn, N; R40-50/53		

*Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.*

							$1\% \leq C < 2,5\%$ : Xn, N; R40-51/53 $0,25\% \leq C < 1\%$ : N; R51/53 $0,025\% \leq C < 0,25\%$ : R52-53
616-165-00-21	Propylbutamid (ISO); (RS)-N-benzyl-2-( $\alpha,\alpha,\alpha,4$ -tetrafluoro- <i>m</i> -toloxy)butyramide	—	113614-08	N; R50-53	N R: 50/53 S: 60-61		$C \geq 0,25\%$ : N; R50/53 $0,025\% \leq C < 0,25\%$ : N; R51/53 $0,0025\% \leq C < 0,025\%$ : R52/53
616-166-00-8	Propazofamid (ISO); 4-chloro-2-cyano- <i>N,N</i> -dimethyl-5- <i>p</i> -tolylimidazole-1-sulfonamide	—	120116-88	N; R50-53	N R: 50/53 S: 60-61		$C \geq 2,5\%$ : N; R50/53 $0,25\% \leq C < 2,5\%$ : N; R51-53 $0,025\% \leq C < 0,25\%$ : R52/53
616-167-00-3	<i>N,N</i> -dibutyl-(2,5-dihydro-5-thioxo-1 <i>H</i> -tetrazol-1-yl)acetamide	418-290-6	168612-06	Xn; R36 R43	Xi R: 36-43 S: (2-)24-26-37		
616-168-00-9	dimethylcarbamoyl-4-(2-sulfonatoethyl)pyridinium	418-440-0	136997-7	R23	Xi R: 43 S: (2-)22-24-37		

*Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.*

616-169-00-44-X	(2,2-dimethylpropanamido)]phenylazo-3-(2-chloro-5-(2-(3-pentadecylphenoxy)butylamido)anilino)-1-(2,4,6-trichlorophenyl)-2-pyrazoline-5-one	420-220-492771-56	R43 R53	Xi R: 43-53 S: (2-)24-37-61		
616-170-00-22-X	(R)-2-amino-2-phenylacetamide	420-370-06485-67-2	Xi; R36 R43	Xi R: 36-43 S: (2-)22-26-36/37		
616-171-00-65-X	para-chlorophenylglycineamide	420-830-0102333-75	Xi; R41 R43	Xi R: 41-43 S: (2-)24-26-37/39		
616-172-00-70-X	(2,2,6,6-tetramethyl-1-oxypiperidin-4-yl)acetamide; (4-acetamido-2,2,6,6-tetramethyl-1-piperidinyloxy)oxidanyl	423-840-314691-89	Xn; R22	Xn R: 22 S: (2-)22		
616-174-00-11-X	butyl-1,3-diazaspiro[4.4]non-1-en-4-one hydrochloride	424-560-4151257-01	Xn; R22 Xi; R36	Xn R: 22-36 S: (2-)22-26		
616-175-00-72-X	(2-hexyldecyloxy)benzamide	431-230-3202483-62	R53	R: 53 S: 61		
616-176-00-21-X	N,N-bis(methoxyethyl)aminoacetanilide	432-530-724294-01	Xn; R22 R52-53	Xn R: 22-52/53 S: (2-)22-24-61		
616-177-00-38-X	(4-(2-(butyl(4-methylphenylsulfonyl)amino)phenylthio)-5-oxo-1-(2,4,6-trichlorophenyl)-4,5-dihydro-1H-	432-970-1217324-98	R53	R: 53 S: 61		

*Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.*

	pyrazole-3-ylamino)-4-chlorophenyl]tetradecanamide; N-[3-({4-[(2-{butyl[(4-methylphenyl)sulfonyl]amino}phenyl)thio]-5-oxo-1-(2,4,6-trichlorophenyl)-4,5-dihydro-1H-pyrazol-3-yl}amino)-4-chlorophenyl]tetradecanamide						
616-178-00-35	(bis(2-methoxyethyl)amino)-2-((2-cyano-4,6-dinitrophenyl)-azo)phenyl)acetamide	434-500-9	52583-35	R53	R: 53 S: 22-61		
616-179-00-9	chloro-N-(4-methylphenyl)acetamide	435-170-9	16634-82	Xi; R41 R43 N; R50-53	Xi; N R: 41-43-50/53 S: (2-)22-26-36/37/39-60-61		
616-180-00-4	N,N-(dimethylamino)thioacetamide hydrochloride	435-470-1	27366-72	Repr. Cat. 2; R61 N; R50-53	T; N R: 61-50/53 S: 53-45-60-61		
616-181-00-4 X	methyl dodecane-1-sulfonamide	435-490-9	17417-32	N; R50-53	N R: 50/53 S: 60-61		
616-182-00-5	(1,3-dimethylbutylidene)-3-hydroxy-2-naphthohydrazide	435-860-1	214417-9	R43 N; R51-53	Xi; N R: 43-51/53 S: (2-)24-37-61		
616-183-00-0	dodecyl-4-methoxybenzamide	442-340-6	1854-15-5	R53	R: 53 S: 61		
616-184-00-6	methyl-N-(5,8,13,14-tetrahydro-5,8,14-trioxonaphth[2,3-c]acridin-6-yl)benzamide	442-560-2	105043-5	R53	R: 53 S: 61		

*Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.*

616-186-00	007-N'-(2-chloro-1,4-phenylene)bis(3-oxobutanamide)	443-010-453641-10	R52-53	R: 52/53 S: 61		
616-188-00	0085,5-dimethyl-2,4-dioxooxazolidin-3-yl)-4,4-dimethyl-3-oxo-N-(2-methoxy-5-octadecanoylamino)phenyl)pentanoic acid amide	443-980-9221215-20	R43 R53	Xi R: 43-53 S: (2-)24-37-61		
616-189-00	0035-(bis-(2-methoxyethyl)-amino]-2-(6-bromo-2-methyl-1,3-dioxo-2,3-dihydro-1H-isoindol-5-ylazo)-phenyl]acetamide	444-780-4452962-97	R53	R: 53 S: 61		
616-190-00	009 decyl-4-nitrobenzamide	445-880-064026-19	R53	R: 53 S: 61		
616-191-00	004 ethyl-N-methyl-N-(3-methylphenyl)butanamide	446-190-2406488-30	Xn; R22 Xi; R36/38 R43 N; R51-53	Xn; N R: 22-36/38-43-51/53 S: (2-)24-26-37-61		
616-192-00 X	00-[2-(3-butoxypropyl)-1,1-dioxo-1,2,4-benzothiadiazin-3-yl]-5'-tert-butyl-2-(5,5-dimethyl-2,4-dioxo-1,3-oxazolidin-3-yl)-2'-[(2-ethylhexyl)thio]acetanilide	448-060-0727678-39	R53	R: 53 S: 61		

*Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.*

616-193-00	449-940-7368450-39R53	0152-(2-butyl-4,6-dicyano-1,3-dioxo-2,3-dihydro-1 <i>H</i> -isoindol-5-ylazo)-5-diethylamino-phenyl]acetamide			R: 53 S: 61		
616-194-00	449-950-134640-92	010-D-diethoxy- <i>N,N</i> -dimethylacetamide			Ki; R36 Xi R: 36 S: (2-)26		
616-196-00	419-990-4	014Sodium salt of 1-hydroxy-4-(β-(4-(1-hydroxy-3,6-disulfo-8-acetylamino-2-naphthylazo)phenoxy)ethoxy)- <i>N</i> -dodecyl-2-naphthamide			N; R50-53 N R: 50/53 S: 60-61		
616-197-00	422-500-1	017Mixture of: potassium <i>N</i> -[3-(dimethyloxidoamino)propyl]-1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluorooctane sulfonamide; <i>N</i> -[3-(dimethyloxidoamino)propyl]-1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluorooctane sulfonamide			Xn; R48/22 Xn R: 48/22 S: (2-)22-36		
616-198-00	423-300-7	013-bis[12-hydroxy-octadecamide- <i>N</i> -methylene]-benzene			R43 R53 Xi R: 43-53 S: (2-)24-37-61		
616-200-00	432-430-3	014Mixture of: <i>N,N'</i> -ethane-1,2-diylbis(hexanamide); 12-hydroxy- <i>N</i> -[2-[(1-oxyhexyl)amino]ethyl]octadecanamide; <i>N,N'</i> -ethane-1,2-			R43 R53 Xi R: 43-53 S: (2-)24-37-61		

*Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.*

	diylbis(12-hydroxyoctadecanamide)					
616-201-0027	hydroxyoctadecanoic acid, reaction products with 1,3-benzenedimethanamine and hexamethylenediamine	432-840-2220926-97	Xn; R20 R53	Xn R: 20-53 S: (2-)22-61		
616-202-0022	Mixture of: 2,2'-[[3,3'-dichloro[1,1'-biphenyl]-4,4'-diyl]bis(azo)]bis[N-(2,4-dimethylphenyl)]-3-oxo-butanamide; 2-[[3,3'-dichloro-4'-[[1[(2,4-dimethylphenyl)amino]carbonyl]-2-oxopropyl]azo][1,1'-biphenyl]-4-yl]azo]-N-(2-methylphenyl)-3-oxo-butanamide; 2-[[3,3'-dichloro-4'-[[1[(2,4-dimethylphenyl)amino]carbonyl]-2-oxopropyl]azo][1,1'-biphenyl]-4-yl]azo]-N-(2-carboxylphenyl)-3-oxo-butanamide	434-330-5—	Carc. Cat. 3; R40 R43 R53	Xn R: 40-43-53 S: (2-)36/37-61		
616-203-0028	Mixture of: N-[5-[bis-(2-methoxyethyl)amino]-2-(2-	442-280-0—	R53	R: 53 S: 61		

*Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.*

	butyl-4,6-dicyano-1,3-dioxo-2,3-dihydro-1 <i>H</i> -isoindol-5-yl-azo)phenyl]acetamide; <i>N</i> -[2-(2-butyl-4,6-dicyano-1,3-dioxo-2,3-dihydro-1 <i>H</i> -isoindol-5-ylazo)5-diethylaminophenyl]acetamide						
616-204-003	<i>N,N'</i> -(methylenedi-4,1-phenylene)bis[ <i>N</i> '-octylurea]	451-060-3	122886-5	R53	R: 53 S: 61		
617-022-007	Mixture of: 1,2-dimethylpropylidene dihydroperoxide; dimethyl 1,2-benzenedicarboxylate	442-480-8	—	O; R7 Xn; R22 C; R34 R43 N; R51-53	O; C; N R: 7-22-34-43-51/53 S: (1/2-)3/7-14-26-36/37/39-45-50-61		
647-017-006	Case	420-150-480	498-15	R42	Xn R: 42 S: (2-)23-45		

## ANNEX 1C

The entries in Annex I with the following Index numbers are deleted:

024-004-01-4, 603-037-01-3, 603-155-00-8, and 611-084-00-9.



---

**Status:** EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

---

(1) OJ 196, 16.8.1967, p. 1.